<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29659554</article-id>
<article-id pub-id-type="pmc">5979570</article-id>
<article-id pub-id-type="doi">10.3390/ijms19041212</article-id>
<article-id pub-id-type="publisher-id">ijms-19-01212</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9158-4467</contrib-id>
<name>
<surname>Vallée</surname>
<given-names>Alexandre</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-19-01212">1</xref>
<xref ref-type="corresp" rid="c1-ijms-19-01212">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Yves</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-19-01212">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guillevin</surname>
<given-names>Rémy</given-names>
</name>
<xref ref-type="aff" rid="af3-ijms-19-01212">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vallée</surname>
<given-names>Jean-Noël</given-names>
</name>
<xref ref-type="aff" rid="af4-ijms-19-01212">4</xref>
<xref ref-type="aff" rid="af5-ijms-19-01212">5</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-19-01212"><label>1</label>Délégation à la Recherche Clinique et à l’Innovation (DRCI), Hôpital Foch, 92150 Suresnes, France</aff>
<aff id="af2-ijms-19-01212"><label>2</label>Centre de Recherche Clinique, Grand Hôpital de l’Est Francilien (GHEF), 77100 Meaux, France; <email>yves.c.lecarpentier@gmail.com</email></aff>
<aff id="af3-ijms-19-01212"><label>3</label>Data Analysis and Computations Through Imaging Modeling-Mathématiques (DACTIM), Unité mixte de recherche (UMR), Centre National de la Recherche Scientifique (CNRS) 7348 (Laboratoire de Mathématiques et Application), University of Poitiers, Centre Hospitalier Universitaire (CHU) de Poitiers, 86000 Poitiers, France; <email>remy.guillevin@chu-poitiers.fr</email></aff>
<aff id="af4-ijms-19-01212"><label>4</label>Centre Hospitalier Universitaire (CHU) Amiens Picardie, University of Picardie Jules Verne (UPJV), 80000 Amiens, France; <email>valleejn@gmail.com</email></aff>
<aff id="af5-ijms-19-01212"><label>5</label>LMA (Laboratoire de Mathématiques et Applications), Unité mixte de recherche (UMR), Centre National de la Recherche Scientifique (CNRS) 7348, Université de Poitiers, 86000 Poitiers, France</aff>
<author-notes>
<corresp id="c1-ijms-19-01212"><label>*</label>Correspondence: <email>alexandre.g.vallee@gmail.com</email>; Tel.: +33-629-303-240</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2018</year>
</pub-date>
<volume>19</volume>
<issue>4</issue>
<elocation-id>1212</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 by the authors.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Demyelination in multiple sclerosis (MS) cells is the site of several energy metabolic abnormalities driven by dysregulation between the opposed interplay of peroxisome proliferator-activated receptor γ (PPARγ) and WNT/β-catenin pathways. We focus our review on the opposing interactions observed in demyelinating processes in MS between the canonical WNT/β-catenin pathway and PPARγ and their reprogramming energy metabolism implications. Demyelination in MS is associated with chronic inflammation, which is itself associated with the release of cytokines by CD4<sup>+</sup> Th17 cells, and downregulation of PPARγ expression leading to the upregulation of the WNT/β-catenin pathway. Upregulation of WNT/β-catenin signaling induces activation of glycolytic enzymes that modify their energy metabolic behavior. Then, in MS cells, a large portion of cytosolic pyruvate is converted into lactate. This phenomenon is called the Warburg effect, despite the availability of oxygen. The Warburg effect is the shift of an energy transfer production from mitochondrial oxidative phosphorylation to aerobic glycolysis. Lactate production is correlated with increased WNT/β-catenin signaling and demyelinating processes by inducing dysfunction of CD4<sup>+</sup> T cells leading to axonal and neuronal damage. In MS, downregulation of PPARγ decreases insulin sensitivity and increases neuroinflammation. PPARγ agonists inhibit Th17 differentiation in CD4<sup>+</sup> T cells and then diminish release of cytokines. In MS, abnormalities in the regulation of circadian rhythms stimulate the WNT pathway to initiate the demyelination process. Moreover, PPARγ contributes to the regulation of some key circadian genes. Thus, PPARγ agonists interfere with reprogramming energy metabolism by directly inhibiting the WNT/β-catenin pathway and circadian rhythms and could appear as promising treatments in MS due to these interactions.</p>
</abstract>
<kwd-group>
<kwd>WNT/β-catenin pathway</kwd>
<kwd>PPARγ</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>energy metabolism</kwd>
<kwd>aerobic glycolysis</kwd>
<kwd>demyelination</kwd>
<kwd>Warburg effect</kwd>
<kwd>circadian rhythms</kwd>
<kwd>clock genes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-19-01212">
<title>1. Introduction</title>
<p>Multiple sclerosis (MS) presents chronic inflammation, immune responses, blood–brain barrier (BBB) breakdown, and demyelination in the white matter of the central nervous system (CNS) [<xref ref-type="bibr" rid="B1-ijms-19-01212">1</xref>,<xref ref-type="bibr" rid="B2-ijms-19-01212">2</xref>]. </p>
<p>In brain and spinal cord areas, chronic inflammation leads to axonal myelin sheath destruction and the progressive loss of neurological functions with neuronal death. The inflammatory process in MS is initiated by the microglia in association with the release of players CD4<sup>+</sup> helper (Th) (Th1 and Th17), the markers of the chronic inflammation [<xref ref-type="bibr" rid="B3-ijms-19-01212">3</xref>]. Pro-inflammatory mediators, such as cytokines (interleukin (IL-6, IL-17, IL-22), tumor necrosis factor α (TNF-α)), are synthetized by Th17 cells, which are the main immune actors in the pathogenesis of MS [<xref ref-type="bibr" rid="B4-ijms-19-01212">4</xref>]. MS can be considered as an autoimmune disease which presents neurological disability and many genetic and environmental determinant etiologies [<xref ref-type="bibr" rid="B5-ijms-19-01212">5</xref>].</p>
<p>Glial cells, called oligodendrocytes (OLs), synthetize myelin sheaths in CNS by wrapping axons with multi-lamellar sheets of plasma membrane which are composed of specific lipids and proteins. Loss of myelinating OLs is considered as the origin of MS pathogenesis [<xref ref-type="bibr" rid="B6-ijms-19-01212">6</xref>,<xref ref-type="bibr" rid="B7-ijms-19-01212">7</xref>,<xref ref-type="bibr" rid="B8-ijms-19-01212">8</xref>,<xref ref-type="bibr" rid="B9-ijms-19-01212">9</xref>]. In white matter lesions of MS, oligodendrocyte precursor cells (OPC) present a stop state and a non-differentiation into myelinating OLs [<xref ref-type="bibr" rid="B6-ijms-19-01212">6</xref>,<xref ref-type="bibr" rid="B10-ijms-19-01212">10</xref>,<xref ref-type="bibr" rid="B11-ijms-19-01212">11</xref>,<xref ref-type="bibr" rid="B12-ijms-19-01212">12</xref>,<xref ref-type="bibr" rid="B13-ijms-19-01212">13</xref>,<xref ref-type="bibr" rid="B14-ijms-19-01212">14</xref>].</p>
<p>Altered cells in MS are derived from exergonic processes and emit heat that flows to the surrounding environment. Several irreversible processes occur by changing reprogramming energy metabolism [<xref ref-type="bibr" rid="B15-ijms-19-01212">15</xref>,<xref ref-type="bibr" rid="B16-ijms-19-01212">16</xref>].</p>
<p>Peroxisome proliferator-activated receptor γ (PPARγ) and the WNT/β-catenin pathway act in an opposite manner in many diseases, including MS [<xref ref-type="bibr" rid="B17-ijms-19-01212">17</xref>,<xref ref-type="bibr" rid="B18-ijms-19-01212">18</xref>]. Numerous autoimmune disorders present this opposed interplay, such as type 1 diabetes [<xref ref-type="bibr" rid="B19-ijms-19-01212">19</xref>,<xref ref-type="bibr" rid="B20-ijms-19-01212">20</xref>], thyroid autoimmunity [<xref ref-type="bibr" rid="B21-ijms-19-01212">21</xref>,<xref ref-type="bibr" rid="B22-ijms-19-01212">22</xref>] and rheumatoid arthritis [<xref ref-type="bibr" rid="B23-ijms-19-01212">23</xref>,<xref ref-type="bibr" rid="B24-ijms-19-01212">24</xref>].</p>
<p>In MS, the dysregulation of both PPARγ [<xref ref-type="bibr" rid="B25-ijms-19-01212">25</xref>] and the WNT/β-catenin pathway [<xref ref-type="bibr" rid="B26-ijms-19-01212">26</xref>] influence several statistical mechanisms by modifying energy metabolism leading to aerobic glycolysis, called the Warburg effect [<xref ref-type="bibr" rid="B27-ijms-19-01212">27</xref>,<xref ref-type="bibr" rid="B28-ijms-19-01212">28</xref>].</p>
<p>PPARγ is a member of the nuclear superfamily of ligand-activated transcription factors which regulates glucose metabolism and cellular homeostasis. WNT ligands belong to the family of glycoproteins participating in the control of cell cycle, cell life and embryogenesis. </p>
<p>The Warburg effect is the shift of an energy transfer production from mitochondrial oxidative phosphorylation to aerobic glycolysis. The Warburg effect was discovered by Otto Warburg in 1930 in cancer processes [<xref ref-type="bibr" rid="B28-ijms-19-01212">28</xref>]. This energy shift is partly due to injury of mitochondrial respiration, leading to an increase of adenosine triphosphate (ATP) production by glycolysis. Indeed, although aerobic glycolysis is less efficient in producing ATP molecules than oxidative phosphorylation, its production cycles are much faster than those of oxidation phosphorylation [<xref ref-type="bibr" rid="B29-ijms-19-01212">29</xref>], which results in higher ATP molecule production than oxidative phosphorylation [<xref ref-type="bibr" rid="B30-ijms-19-01212">30</xref>]. Recent studies have shown that this phenomenon is not specific to cancers but is also observed in non-tumor diseases, such as MS [<xref ref-type="bibr" rid="B31-ijms-19-01212">31</xref>]. </p>
<p>In parallel, dysregulation of circadian rhythms (CRs) has been observed in MS [<xref ref-type="bibr" rid="B32-ijms-19-01212">32</xref>]. This dysfunction leads to upregulation of the canonical WNT/β-catenin pathway that contributes to MS pathogenesis. PPARγ can control CRs by regulating some key circadian genes, like Bmal1 (brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1) [<xref ref-type="bibr" rid="B33-ijms-19-01212">33</xref>] and can directly target the WNT pathway [<xref ref-type="bibr" rid="B34-ijms-19-01212">34</xref>] and energy balance in CNS [<xref ref-type="bibr" rid="B35-ijms-19-01212">35</xref>]. By acting on these systems, PPARγ appears as an interesting therapeutic pathway. In MS, the opposed interplay between PPARγ and the WNT/β-catenin pathway has a major role in the dysregulation of energy metabolism and the disruption of CRs. Several energy balance abnormalities found in MS are induced by several cellular processes involved in both of these. We focus this review on the opposing interactions observed in MS between PPARγ and the canonical WNT/β-catenin pathway and their reprogramming energy metabolism implications.</p>
</sec>
<sec id="sec2-ijms-19-01212">
<title>2. PPARγ</title>
<p>Peroxisome proliferator-activated receptor γ (PPARγ) is an orphan nuclear receptor which is a member of the nuclear superfamily of ligand-activated transcription factors [<xref ref-type="bibr" rid="B36-ijms-19-01212">36</xref>,<xref ref-type="bibr" rid="B37-ijms-19-01212">37</xref>]. PPARγ is composed of a ligand binding domain which is hydrophobic and a type II zinc finger DNA-binding domain [<xref ref-type="bibr" rid="B38-ijms-19-01212">38</xref>].</p>
<p>PPARγ ligands form a heterodimer with the retinoic X receptor (RXR). RXR is a 9-<italic>cis</italic> retinoic acid receptor. The heterodimer binds to peroxisome proliferator response element (PPRE) to activate several target genes [<xref ref-type="bibr" rid="B39-ijms-19-01212">39</xref>]. PPARγ is highly expressed in adipose tissues [<xref ref-type="bibr" rid="B40-ijms-19-01212">40</xref>] and in cardiac and skeletal muscle, pancreatic β-cells, kidney, macrophages [<xref ref-type="bibr" rid="B41-ijms-19-01212">41</xref>], and other vascular cells, like endothelial cells [<xref ref-type="bibr" rid="B42-ijms-19-01212">42</xref>,<xref ref-type="bibr" rid="B43-ijms-19-01212">43</xref>].</p>
<p>PPARγ expression is implicated in numerous homeostasis pathways such as glucose and lipid metabolism. Likewise, PPARγ expression is implicated in migration, apoptosis, cell growth, antioxidant and inflammatory responses [<xref ref-type="bibr" rid="B39-ijms-19-01212">39</xref>,<xref ref-type="bibr" rid="B44-ijms-19-01212">44</xref>,<xref ref-type="bibr" rid="B45-ijms-19-01212">45</xref>]. PPARγ is normally little expressed in CNS [<xref ref-type="bibr" rid="B46-ijms-19-01212">46</xref>], but its expression is found in neurons, OLs, astrocytes, microglia/macrophages [<xref ref-type="bibr" rid="B47-ijms-19-01212">47</xref>], T and B lymphocytes, dendritic cells [<xref ref-type="bibr" rid="B48-ijms-19-01212">48</xref>] and brain endothelial cells [<xref ref-type="bibr" rid="B49-ijms-19-01212">49</xref>]. PPARγ can repress inflammation by decreasing nuclear factor-κB (NF-κB) activity [<xref ref-type="bibr" rid="B50-ijms-19-01212">50</xref>].</p>
<p>Synthetic ligands of PPARγ are prostaglandins like 15-deoxy-Δ, 14 prostaglandin J2 [<xref ref-type="bibr" rid="B51-ijms-19-01212">51</xref>], hydroxyl octadecadienoic acid with derivatives of fatty acid oxidation [<xref ref-type="bibr" rid="B52-ijms-19-01212">52</xref>] and lysophosphatidic acid (LPA) [<xref ref-type="bibr" rid="B53-ijms-19-01212">53</xref>]. Pioglitazone and rosiglitazone are thiazolidinediones (TZD) which are synthetic PPARγ ligands [<xref ref-type="bibr" rid="B52-ijms-19-01212">52</xref>]. </p>
</sec>
<sec id="sec3-ijms-19-01212">
<title>3. Canonical WNT/β-Catenin Pathway (<xref ref-type="fig" rid="ijms-19-01212-f001">Figure 1</xref>)</title>
<p>Canonical WNT/β-catenin pathway is named as the discovery of the cascade gene “W”ingless in drosophila and its homologue in mice “INT”(Integration site) [<xref ref-type="bibr" rid="B54-ijms-19-01212">54</xref>] (<xref ref-type="fig" rid="ijms-19-01212-f001">Figure 1</xref>). The WNT/β-catenin pathway is involved in numerous life cycles, such as embryogenesis in migration, proliferation, differentiation, apoptosis and cell polarity [<xref ref-type="bibr" rid="B55-ijms-19-01212">55</xref>]. Deregulation of the WNT/β-catenin pathway is observed in several pathologies, such as cancers, fibrosis, neurodegenerative diseases, and atherosclerosis, and its targeting appears as an emerging therapeutic pathway [<xref ref-type="bibr" rid="B56-ijms-19-01212">56</xref>].</p>
<p>WNT ligands are glycoproteins, which activate the canonical WNT/β-catenin pathway [<xref ref-type="bibr" rid="B57-ijms-19-01212">57</xref>]. Extracellular WNT ligands bind the receptor Frizzled (FZD) and then stimulate the co-receptor Low-Density Lipoprotein (LDL) receptor-related proteins 5 and 6 (LRP 5/6) [<xref ref-type="bibr" rid="B58-ijms-19-01212">58</xref>]. </p>
<p>β-catenin is considered as the main molecule of the canonical WNT pathway. Its major function is transcriptional activity. In physiologic conditions, cytoplasmic β-catenin is in constant turnover between synthetized and destroyed intracellular cycles. </p>
<p>Cytosolic β-catenin is maintained at a minimal level through the activation of the β-catenin destruction complex, which is formed by a combination of AXIN (a cytoplasmic protein regulating G-protein signaling), glycogen synthase kinase-3β (GSK-3β, a serine-theronine kinase), adenomatous polyposis coli (APC, a tumor suppressor gene), and casein kinase 1 (CK-1, a serine/threonine-selective enzyme) [<xref ref-type="bibr" rid="B59-ijms-19-01212">59</xref>]. CK-1 and GSK-3β target β-catenin by phosphorylating the serine and threonine residues located in the amino acid terminus [<xref ref-type="bibr" rid="B60-ijms-19-01212">60</xref>,<xref ref-type="bibr" rid="B61-ijms-19-01212">61</xref>,<xref ref-type="bibr" rid="B62-ijms-19-01212">62</xref>]. CK-1 phosphorylates an N-terminus of β-catenin and GSK-3β phosphorylates a threonine 41 (Th41), Ser33 and Ser37 sites of β-catenin [<xref ref-type="bibr" rid="B55-ijms-19-01212">55</xref>,<xref ref-type="bibr" rid="B63-ijms-19-01212">63</xref>]. These phosphorylations result in the recruiting of APC in the destruction complex. APC modulates the degradation of the cytosolic β-catenin into the proteasome through its tumor suppressor properties [<xref ref-type="bibr" rid="B59-ijms-19-01212">59</xref>,<xref ref-type="bibr" rid="B64-ijms-19-01212">64</xref>].</p>
<p>Activation of the WNT/β-catenin pathway is characterized by the initiation of WNT ligands and their interactions with FZD and LRP 5/6 co-receptors [<xref ref-type="bibr" rid="B65-ijms-19-01212">65</xref>]. This binding stimulates Disheveled (DSH) to inhibit the destruction complex and to permit cytosolic β-catenin accumulation. Nuclear β-catenin binds T-cell factor/lymphoid enhancer factor (TCF/LEF) to activate several WNT target genes, such as c-Myc and cyclin D1 [<xref ref-type="bibr" rid="B66-ijms-19-01212">66</xref>,<xref ref-type="bibr" rid="B67-ijms-19-01212">67</xref>]. </p>
<p>Demyelinating events present an upregulation of the WNT/β-catenin pathway correlated with a release of pro-inflammatory cytokines [<xref ref-type="bibr" rid="B68-ijms-19-01212">68</xref>]. Moreover, PPARγ stimulation has a beneficial role in MS [<xref ref-type="bibr" rid="B69-ijms-19-01212">69</xref>,<xref ref-type="bibr" rid="B70-ijms-19-01212">70</xref>] through the decrease of neuroinflammation [<xref ref-type="bibr" rid="B71-ijms-19-01212">71</xref>] and the downregulation of the WNT/β-catenin pathway in MS [<xref ref-type="bibr" rid="B17-ijms-19-01212">17</xref>,<xref ref-type="bibr" rid="B18-ijms-19-01212">18</xref>]. PPARγ agonists are considered as potential therapeutic perspectives against neuroinflammation and neurodegeneration [<xref ref-type="bibr" rid="B72-ijms-19-01212">72</xref>]. In MS, these two pathways operate in an opposed interplay [<xref ref-type="bibr" rid="B18-ijms-19-01212">18</xref>] and their dysregulations lead to energy metabolism reprogramming. The objectives of this review are to describe this opposed crosstalk with circadian rhythms regulation, and to better understand the energy remodeling aspect, called the Warburg effect, observed in MS and the potential therapeutic benefits of targeting these two pathways to improve MS-related symptoms.</p>
</sec>
<sec id="sec4-ijms-19-01212">
<title>4. Crosstalk between PPARγ and Canonical WNT/β-Catenin Pathway in Diseases</title>
<p>The opposed interplay between the canonical WNT/β-catenin pathway and PPARγ has been observed in numerous pathologies. Cancers, such as gliomas [<xref ref-type="bibr" rid="B73-ijms-19-01212">73</xref>,<xref ref-type="bibr" rid="B74-ijms-19-01212">74</xref>,<xref ref-type="bibr" rid="B75-ijms-19-01212">75</xref>] and colon cancer [<xref ref-type="bibr" rid="B76-ijms-19-01212">76</xref>], present an upregulation of the canonical WNT/β-catenin pathway associated with a decrease of PPARγ expression [<xref ref-type="bibr" rid="B77-ijms-19-01212">77</xref>]. The process of fibrosis exhibits the same mechanism [<xref ref-type="bibr" rid="B78-ijms-19-01212">78</xref>,<xref ref-type="bibr" rid="B79-ijms-19-01212">79</xref>,<xref ref-type="bibr" rid="B80-ijms-19-01212">80</xref>]. Neurodegenerative diseases are classified in two categories [<xref ref-type="bibr" rid="B34-ijms-19-01212">34</xref>], i.e., diseases that present a downregulation of the canonical WNT/β-catenin pathway and an upregulation of PPARγ, such as Alzheimer’s disease [<xref ref-type="bibr" rid="B81-ijms-19-01212">81</xref>,<xref ref-type="bibr" rid="B82-ijms-19-01212">82</xref>,<xref ref-type="bibr" rid="B83-ijms-19-01212">83</xref>], and diseases with an upregulation of the canonical WNT/β-catenin pathway whereas PPARγ is decreased, such as exudative age related macular degeneration [<xref ref-type="bibr" rid="B84-ijms-19-01212">84</xref>,<xref ref-type="bibr" rid="B85-ijms-19-01212">85</xref>], amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="B86-ijms-19-01212">86</xref>], and multiple sclerosis [<xref ref-type="bibr" rid="B18-ijms-19-01212">18</xref>].</p>
<p>Numerous studies have suggested that PPARγ may be considered as a negative β-catenin target [<xref ref-type="bibr" rid="B87-ijms-19-01212">87</xref>,<xref ref-type="bibr" rid="B88-ijms-19-01212">88</xref>]. The β-catenin pathway can decrease PPARγ expression [<xref ref-type="bibr" rid="B89-ijms-19-01212">89</xref>,<xref ref-type="bibr" rid="B90-ijms-19-01212">90</xref>,<xref ref-type="bibr" rid="B91-ijms-19-01212">91</xref>,<xref ref-type="bibr" rid="B92-ijms-19-01212">92</xref>,<xref ref-type="bibr" rid="B93-ijms-19-01212">93</xref>,<xref ref-type="bibr" rid="B94-ijms-19-01212">94</xref>,<xref ref-type="bibr" rid="B95-ijms-19-01212">95</xref>,<xref ref-type="bibr" rid="B96-ijms-19-01212">96</xref>,<xref ref-type="bibr" rid="B97-ijms-19-01212">97</xref>,<xref ref-type="bibr" rid="B98-ijms-19-01212">98</xref>]. Indeed, PPARγ and WNT/β-catenin pathway interact via a catenin-binding domain within PPARγ and a TCF/LEF β-catenin domain [<xref ref-type="bibr" rid="B99-ijms-19-01212">99</xref>,<xref ref-type="bibr" rid="B100-ijms-19-01212">100</xref>,<xref ref-type="bibr" rid="B101-ijms-19-01212">101</xref>,<xref ref-type="bibr" rid="B102-ijms-19-01212">102</xref>].</p>
<p>The decrease of the WNT/β-catenin pathway stimulates the expression of PPARγ [<xref ref-type="bibr" rid="B103-ijms-19-01212">103</xref>], while the increase of PPARγ expression inhibits β-catenin levels in numerous cellular systems [<xref ref-type="bibr" rid="B104-ijms-19-01212">104</xref>,<xref ref-type="bibr" rid="B105-ijms-19-01212">105</xref>,<xref ref-type="bibr" rid="B106-ijms-19-01212">106</xref>]. Troglitazone, a PPARγ agonist, can downregulate c-Myc expression, a WNT target gene [<xref ref-type="bibr" rid="B107-ijms-19-01212">107</xref>]. PPARγ agonists, can activate WNT inhibitors, such as Dicckopf-1 (DKK1) [<xref ref-type="bibr" rid="B108-ijms-19-01212">108</xref>] and GSK-3β [<xref ref-type="bibr" rid="B109-ijms-19-01212">109</xref>] to decrease β-catenin levels. In parallel, the WNT target COUP II can decrease PPARγ [<xref ref-type="bibr" rid="B110-ijms-19-01212">110</xref>]. Inflammatory cytokines and cellular pathways, such as WNT/β-catenin pathway, interleukin 1 (IL-1) and TNF-α, can inhibit PPARγ expression [<xref ref-type="bibr" rid="B111-ijms-19-01212">111</xref>,<xref ref-type="bibr" rid="B112-ijms-19-01212">112</xref>,<xref ref-type="bibr" rid="B113-ijms-19-01212">113</xref>].</p>
</sec>
<sec id="sec5-ijms-19-01212">
<title>5. PPARγ and the Canonical WNT/β-Catenin Pathway in MS</title>
<sec id="sec5dot1-ijms-19-01212">
<title>5.1. PPARγ in MS</title>
<p>Several studies have shown that PPARγ agonists can reduce the clinical expression of experimental autoimmune encephalomyelitis (EAE) models of MS (<xref ref-type="table" rid="ijms-19-01212-t001">Table 1</xref>). In EAE models, the PPARγ agonist 15-deoxy-Δ(12,14)-prostaglandin acts by inhibiting NF-κB activity [<xref ref-type="bibr" rid="B114-ijms-19-01212">114</xref>,<xref ref-type="bibr" rid="B115-ijms-19-01212">115</xref>,<xref ref-type="bibr" rid="B116-ijms-19-01212">116</xref>]. In addition, PPARγ deficiency has been shown to exacerbate the clinical symptoms of EAE models [<xref ref-type="bibr" rid="B117-ijms-19-01212">117</xref>]. The downregulation of PPARγ during demyelination in MS is well-described in previous studies [<xref ref-type="bibr" rid="B18-ijms-19-01212">18</xref>]. However, the stimulation of PPARγ [<xref ref-type="bibr" rid="B118-ijms-19-01212">118</xref>,<xref ref-type="bibr" rid="B119-ijms-19-01212">119</xref>] leads to decreased inflammation and permits the remyelination in oligodendrocytes (OLs) models of MS [<xref ref-type="bibr" rid="B120-ijms-19-01212">120</xref>]. The overexpression of PPARγ is correlated with neuroprotection in both OLs and neurons [<xref ref-type="bibr" rid="B121-ijms-19-01212">121</xref>,<xref ref-type="bibr" rid="B122-ijms-19-01212">122</xref>,<xref ref-type="bibr" rid="B123-ijms-19-01212">123</xref>,<xref ref-type="bibr" rid="B124-ijms-19-01212">124</xref>,<xref ref-type="bibr" rid="B125-ijms-19-01212">125</xref>,<xref ref-type="bibr" rid="B126-ijms-19-01212">126</xref>,<xref ref-type="bibr" rid="B127-ijms-19-01212">127</xref>,<xref ref-type="bibr" rid="B128-ijms-19-01212">128</xref>]. Th17 differentiation is decreased by PPARγ agonists in both murine CD4<sup>+</sup> T cells and in human models [<xref ref-type="bibr" rid="B129-ijms-19-01212">129</xref>]. In CNS-infiltrating CD4<sup>+</sup> T cells, IL-17 expression is diminished by PPARγ overexpression [<xref ref-type="bibr" rid="B130-ijms-19-01212">130</xref>]. The anti-inflammatory role of PPARγ is responsible for both the decreased release of inflammatory cytokines [<xref ref-type="bibr" rid="B41-ijms-19-01212">41</xref>,<xref ref-type="bibr" rid="B131-ijms-19-01212">131</xref>,<xref ref-type="bibr" rid="B132-ijms-19-01212">132</xref>], and the expansion of encephalitogenic Th1 [<xref ref-type="bibr" rid="B117-ijms-19-01212">117</xref>], Th17 cells [<xref ref-type="bibr" rid="B129-ijms-19-01212">129</xref>] and B lymphocytes [<xref ref-type="bibr" rid="B133-ijms-19-01212">133</xref>]. Lovastatin induces the expression of PPARγ in the central nervous system (CNS) of EAE models [<xref ref-type="bibr" rid="B134-ijms-19-01212">134</xref>]. However, simvastatin impedes the remyelination mechanism in cuprizone-CNS demyelinating models (non-EAE-models) [<xref ref-type="bibr" rid="B135-ijms-19-01212">135</xref>,<xref ref-type="bibr" rid="B136-ijms-19-01212">136</xref>].</p>
</sec>
<sec id="sec5dot2-ijms-19-01212">
<title>5.2. Demyelination and Activation of WNT/β-Catenin Pathway</title>
<p>Several studies have shown that the WNT/β-catenin pathway is overexpressed during the demyelination process (for review, see [<xref ref-type="bibr" rid="B18-ijms-19-01212">18</xref>]) (<xref ref-type="table" rid="ijms-19-01212-t001">Table 1</xref>). The expression of WNT/β-catenin pathway is overexpressed in the spinal cord dorsal horn (SCDH) in EAE models of mice [<xref ref-type="bibr" rid="B68-ijms-19-01212">68</xref>]. The increase of the β-catenin inhibitor indomethacin is known to decrease mechanical allodynia in EAE mice [<xref ref-type="bibr" rid="B68-ijms-19-01212">68</xref>]. In EAE models, over-activation of the WNT/β-catenin pathway impairs and delays OPC differentiation [<xref ref-type="bibr" rid="B137-ijms-19-01212">137</xref>]. The WNT/β-catenin pathway, by stimulating pro-inflammatory cytokines, has a major role in neuropathic pain pathogenesis [<xref ref-type="bibr" rid="B138-ijms-19-01212">138</xref>]. β-catenin accumulation and nuclear transcription are associated with alteration of endothelial adherens in experimental models [<xref ref-type="bibr" rid="B139-ijms-19-01212">139</xref>,<xref ref-type="bibr" rid="B140-ijms-19-01212">140</xref>] and in MS brain tissue [<xref ref-type="bibr" rid="B141-ijms-19-01212">141</xref>].</p>
</sec>
<sec id="sec5dot3-ijms-19-01212">
<title>5.3. Opposed Interaction between PPARγ and WNT Pathway in MS</title>
<p>In MS models, moringin (4-[α-<sc>l</sc>-rhamnopyranosyloxy]-benzyl isothiocyanate) can modulate neuroinflammation through both decreased β-catenin signaling and increased PPARγ expression [<xref ref-type="bibr" rid="B142-ijms-19-01212">142</xref>]. Moringin can also repress inflammatory factors, such as IL-1, IL-6 and cyclo-oxygenase-2 (COX2) in EAE mice by increasing PPARγ levels [<xref ref-type="bibr" rid="B142-ijms-19-01212">142</xref>]. In MS, moringin is known to protect against neurodegenerative disorders [<xref ref-type="bibr" rid="B143-ijms-19-01212">143</xref>,<xref ref-type="bibr" rid="B144-ijms-19-01212">144</xref>].</p>
</sec>
</sec>
<sec id="sec6-ijms-19-01212">
<title>6. Reprogramming Energy Metabolism in Demyelination</title>
<sec id="sec6dot1-ijms-19-01212">
<title>6.1. Aerobic Glycolysis </title>
<p>Aerobic glycolysis, called the Warburg effect, is the conversion of glucose to lactate in the presence of oxygen sufficient to support glucose catabolism via the tricarboxylic acid (TCA) cycle with oxidative phosphorylation [<xref ref-type="bibr" rid="B28-ijms-19-01212">28</xref>] (<xref ref-type="fig" rid="ijms-19-01212-f002">Figure 2</xref>). Numerous studies have shown that the canonical WNT/β-catenin pathway stimulates aerobic glycolysis and glycolytic enzymes such as glucose transporter (Glut), hexokinase (HK), pyruvate kinase M2 (PKM2), lactate dehydrogenase A (LDH-A), monocarboxylate transporter 1 (MCT-1) [<xref ref-type="bibr" rid="B27-ijms-19-01212">27</xref>,<xref ref-type="bibr" rid="B73-ijms-19-01212">73</xref>,<xref ref-type="bibr" rid="B77-ijms-19-01212">77</xref>,<xref ref-type="bibr" rid="B85-ijms-19-01212">85</xref>,<xref ref-type="bibr" rid="B145-ijms-19-01212">145</xref>,<xref ref-type="bibr" rid="B146-ijms-19-01212">146</xref>]. An increased rate of glucose metabolism is correlated with activation of the PI3K/Akt pathway [<xref ref-type="bibr" rid="B147-ijms-19-01212">147</xref>]. The WNT/β-catenin pathway directly stimulates PI3K/Akt signaling [<xref ref-type="bibr" rid="B148-ijms-19-01212">148</xref>,<xref ref-type="bibr" rid="B149-ijms-19-01212">149</xref>]. Activation of the PI3K/Akt pathway leads to HIF-1α stimulation (hypoxia-inducible factor 1-α) [<xref ref-type="bibr" rid="B150-ijms-19-01212">150</xref>] to induce overexpression of glycolytic enzymes such as Glut, LDH-A, pyruvate dehydrogenase kinase 1 (PDK1) and PKM2 [<xref ref-type="bibr" rid="B150-ijms-19-01212">150</xref>,<xref ref-type="bibr" rid="B151-ijms-19-01212">151</xref>]. The allosteric enzyme Phosphofructokinase (PFK) catalyzes the conversion between β-<sc>d</sc>-fructose-6-phosphate and β-<sc>d</sc>-fructose-1,6-biphosphate. This reaction, by using ATP, leads to glycolytic oscillations and can be organized in time and space driven by PFK with a positive feedback responsible for periodic behavior [<xref ref-type="bibr" rid="B152-ijms-19-01212">152</xref>]. </p>
</sec>
<sec id="sec6dot2-ijms-19-01212">
<title>6.2. Aerobic Glycolysis in MS</title>
<p>An imbalance between energy production and consumption has been observed in MS [<xref ref-type="bibr" rid="B153-ijms-19-01212">153</xref>,<xref ref-type="bibr" rid="B154-ijms-19-01212">154</xref>,<xref ref-type="bibr" rid="B155-ijms-19-01212">155</xref>]. Decrease of oxidative phosphorylation and mRNA deletions observed in MS neuronal cell bodies indicate a mitochondrial dysregulation [<xref ref-type="bibr" rid="B156-ijms-19-01212">156</xref>,<xref ref-type="bibr" rid="B157-ijms-19-01212">157</xref>]. Indeed, alteration of energy metabolism is observed in urine [<xref ref-type="bibr" rid="B158-ijms-19-01212">158</xref>] and in serum of MS patients [<xref ref-type="bibr" rid="B159-ijms-19-01212">159</xref>]. Activation of aerobic glycolysis and decrease of oxidative phosphorylation aggravate MS pathogenesis by inducing dysfunction of CD4<sup>+</sup> T cell [<xref ref-type="bibr" rid="B160-ijms-19-01212">160</xref>]. CD4<sup>+</sup> T cell dysregulation has a major role in MS pathogenesis by aggravating axonal and neuronal damage [<xref ref-type="bibr" rid="B1-ijms-19-01212">1</xref>,<xref ref-type="bibr" rid="B161-ijms-19-01212">161</xref>]. </p>
<p>Inhibition of aerobic glycolysis in MS by copaxone restores mitochondrial activity and then diminish CD4<sup>+</sup> T cell dysregulation [<xref ref-type="bibr" rid="B162-ijms-19-01212">162</xref>]. Glycolytic metabolism reduces ROS (reactive oxygen species) production, oxidative damage and promotes the production of lipids and fatty acid required by OLs for myelin production [<xref ref-type="bibr" rid="B163-ijms-19-01212">163</xref>,<xref ref-type="bibr" rid="B164-ijms-19-01212">164</xref>,<xref ref-type="bibr" rid="B165-ijms-19-01212">165</xref>].</p>
<p>Neuronal cell death and astrocytic inflammation processes are associated with the increase of glycolytic activity [<xref ref-type="bibr" rid="B166-ijms-19-01212">166</xref>,<xref ref-type="bibr" rid="B167-ijms-19-01212">167</xref>]. Shunt of TCA cycle by decrease of pyruvate dehydrogenase (PDH) activity is associated with neurodegeneration [<xref ref-type="bibr" rid="B168-ijms-19-01212">168</xref>,<xref ref-type="bibr" rid="B169-ijms-19-01212">169</xref>]. Lactate metabolism is upregulated upon the increase of aerobic glycolysis in MS [<xref ref-type="bibr" rid="B170-ijms-19-01212">170</xref>,<xref ref-type="bibr" rid="B171-ijms-19-01212">171</xref>]. The increase in lactate levels is correlated with the progression of MS [<xref ref-type="bibr" rid="B172-ijms-19-01212">172</xref>,<xref ref-type="bibr" rid="B173-ijms-19-01212">173</xref>]. Reduction of oxidative phosphorylation, shunt of the TCA cycle and activation of aerobic glycolysis inducing lactate production are observed in MS lesions [<xref ref-type="bibr" rid="B31-ijms-19-01212">31</xref>,<xref ref-type="bibr" rid="B159-ijms-19-01212">159</xref>]. Recently, magnetic resonance spectroscopy and positron emission tomography (PET) have shown that lactate levels are increased in MS lesions [<xref ref-type="bibr" rid="B170-ijms-19-01212">170</xref>,<xref ref-type="bibr" rid="B174-ijms-19-01212">174</xref>] and that lactate concentration in the cerebral spinal fluid is associated with the number of inflammatory plaques and mitochondrial dysregulation in MS [<xref ref-type="bibr" rid="B175-ijms-19-01212">175</xref>,<xref ref-type="bibr" rid="B176-ijms-19-01212">176</xref>,<xref ref-type="bibr" rid="B177-ijms-19-01212">177</xref>]. Modulation of aerobic glycolysis appears as a potential treatment for myelin maintenance in MS lesions [<xref ref-type="bibr" rid="B26-ijms-19-01212">26</xref>].</p>
</sec>
</sec>
<sec id="sec7-ijms-19-01212">
<title>7. Circadian Rhythms in MS</title>
<sec id="sec7dot1-ijms-19-01212">
<title>7.1. Circadian Rhythms, Definition</title>
<p>Several biologic mechanisms in the body are controlled by the circadian “clock” (circadian locomotors output cycles kaput). The circadian clock is located in the hypothalamic suprachiasmatic nucleus (SCN). CRs are endogenous and entrainable free-running periods that last approximately 24 h. Numerous transcription determinants are responsible for the regulation of CRs. They are called circadian locomotor output cycles kaput (Clock), brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1 (Bmal1), Period 1 (Per1), Period 2 (Per2), Period 3 (Per3), and Cryptochrome (Cry 1 and Cry 2) [<xref ref-type="bibr" rid="B178-ijms-19-01212">178</xref>,<xref ref-type="bibr" rid="B179-ijms-19-01212">179</xref>] (<xref ref-type="fig" rid="ijms-19-01212-f003">Figure 3</xref>). These transcription factors are controlled by positive and negative feedbacks mediated by CRs [<xref ref-type="bibr" rid="B180-ijms-19-01212">180</xref>,<xref ref-type="bibr" rid="B181-ijms-19-01212">181</xref>]. Clock and Bmal1 heterodimerize and then initiate transcription of Per1, Per2, Cry1 and Cry2 [<xref ref-type="bibr" rid="B182-ijms-19-01212">182</xref>]. The Per/Cry heterodimer can inhibit its activation through negative feedback. It translocates back to the nucleus to directly inhibit the Clock/Bmal1 complex and then inhibits its own transcription [<xref ref-type="bibr" rid="B182-ijms-19-01212">182</xref>]. </p>
<p>The Clock/Bmal1 heterodimer activates the transcription of retinoic acid-related orphan nuclear receptors, Rev-Erbs and retinoid-related orphan receptors (RORs). By a positive self-regulation RORs can activate Bmal1 transcription, whereas Rev-Erbs can repress their transcription through negative feedback [<xref ref-type="bibr" rid="B182-ijms-19-01212">182</xref>]. </p>
</sec>
<sec id="sec7dot2-ijms-19-01212">
<title>7.2. Circadian Rhythm Disruption in MS</title>
<p>Several studies have shown that circadian rhythms have a main role in MS [<xref ref-type="bibr" rid="B183-ijms-19-01212">183</xref>]. Late-night shift work in MS patients is associated with disruption of circadian rhythms and sleep [<xref ref-type="bibr" rid="B184-ijms-19-01212">184</xref>,<xref ref-type="bibr" rid="B185-ijms-19-01212">185</xref>]. Indeed, sleep dysregulation worsens EAE symptoms [<xref ref-type="bibr" rid="B186-ijms-19-01212">186</xref>] by increasing the infiltration of inflammatory cells in the CNS, such as CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="B186-ijms-19-01212">186</xref>]. EAE severity is associated with both sleep disruption and degree of sleep fragmentation [<xref ref-type="bibr" rid="B187-ijms-19-01212">187</xref>]. Few studies have examined CRs dysregulation in MS. However, MS is associated with many symptoms such as hypertension, heart disease, anxiety, depression and sleep disturbances [<xref ref-type="bibr" rid="B188-ijms-19-01212">188</xref>,<xref ref-type="bibr" rid="B189-ijms-19-01212">189</xref>]. Sleep disorders observed in MS patients [<xref ref-type="bibr" rid="B190-ijms-19-01212">190</xref>] are characterized by prolonged sleep latency and frequent nocturnal awakening [<xref ref-type="bibr" rid="B191-ijms-19-01212">191</xref>]. In MS, fatigue symptom is associated with CRs abnormalities [<xref ref-type="bibr" rid="B192-ijms-19-01212">192</xref>,<xref ref-type="bibr" rid="B193-ijms-19-01212">193</xref>], such as sleep phase syndrome and irregular sleep wake pattern. In MS, dorsolateral hypothalamic neurons secrete less neuropeptide hypocretin-1/orexin-A [<xref ref-type="bibr" rid="B194-ijms-19-01212">194</xref>]. The Orexin-A system is responsible for the modulation of sleep-wake cycle [<xref ref-type="bibr" rid="B195-ijms-19-01212">195</xref>]. Decreased orexin-A levels lead to the promotion of consolidated night sleep [<xref ref-type="bibr" rid="B196-ijms-19-01212">196</xref>]. </p>
<p>Hypersomnia observed in MS patients is associated with low cerebrospinal fluid (CSF) orexin-A and hypothalamic lesions [<xref ref-type="bibr" rid="B197-ijms-19-01212">197</xref>]. Inflammation may suppress the orexin-A system [<xref ref-type="bibr" rid="B198-ijms-19-01212">198</xref>] through the overexpression of cytokines, TNF-α and interferon γ (IFN-γ) leading to fatigue syndrome in MS patients [<xref ref-type="bibr" rid="B199-ijms-19-01212">199</xref>]. </p>
<p>The orexin-A system is influenced by seasonal fluctuations and day length [<xref ref-type="bibr" rid="B200-ijms-19-01212">200</xref>]. Demyelination process may put MS patients at risk for CR disorders [<xref ref-type="bibr" rid="B201-ijms-19-01212">201</xref>]. Seasonal fluctuations observed in MS may be due to variations of melatonin levels which increase in winter and decrease in summer [<xref ref-type="bibr" rid="B202-ijms-19-01212">202</xref>]. Moreover, this seasonal variation could also act through the birth month in susceptibility to developing MS [<xref ref-type="bibr" rid="B203-ijms-19-01212">203</xref>,<xref ref-type="bibr" rid="B204-ijms-19-01212">204</xref>]. Cytokine and chemokine expression in lymphoid tissues present some seasonal variation in EAE mice [<xref ref-type="bibr" rid="B204-ijms-19-01212">204</xref>,<xref ref-type="bibr" rid="B205-ijms-19-01212">205</xref>]. </p>
<p>By inducing Rev-Erbs, CRs can regulate the balance of Th17/Th1/Treg in EAE mice [<xref ref-type="bibr" rid="B206-ijms-19-01212">206</xref>]. The number of Th17 cells decreases during the acute phase of MS and is associated with melatonin levels [<xref ref-type="bibr" rid="B206-ijms-19-01212">206</xref>]. </p>
</sec>
<sec id="sec7dot3-ijms-19-01212">
<title>7.3. Interaction between WNT/β-Catenin Pathway and Circadian Rhythms</title>
<p>The WNT/β-catenin pathway is downstream of the RORs regulation factors and contains diverse putative Bmal1 clock-binding sites within its promoter [<xref ref-type="bibr" rid="B207-ijms-19-01212">207</xref>]. By these interactions, circadian genes can regulate cell cycle progression through the WNT pathway [<xref ref-type="bibr" rid="B208-ijms-19-01212">208</xref>] (<xref ref-type="fig" rid="ijms-19-01212-f004">Figure 4</xref>). Expression of WNT pathway can be downregulated by Bmal1 knockdown [<xref ref-type="bibr" rid="B209-ijms-19-01212">209</xref>]. Expression levels of WNT-related genes in wild-type mice are higher than levels of WNT-related genes with Bmal1 knockdown mice [<xref ref-type="bibr" rid="B210-ijms-19-01212">210</xref>,<xref ref-type="bibr" rid="B211-ijms-19-01212">211</xref>]. Bmal1 appears to be upregulated in MS [<xref ref-type="bibr" rid="B212-ijms-19-01212">212</xref>]. Cell proliferation and cell cycle progression are regulated by Bmal1 via stimulation of the canonical WNT/β-catenin pathway [<xref ref-type="bibr" rid="B213-ijms-19-01212">213</xref>]. Bmal1 activation increases β-catenin transcription and decreases both β-catenin degradation and GSK-3β activation [<xref ref-type="bibr" rid="B214-ijms-19-01212">214</xref>]. Per2 degradation induced by β-catenin involves the dysregulation of circadian genes in intestinal mucosa of ApcMin/+ mice [<xref ref-type="bibr" rid="B215-ijms-19-01212">215</xref>]. </p>
<p>In normal circumstances, the core circadian genes work in accurate feedback loops and keep the molecular clockworks in the SCN. They permit regulation of peripheral clocks [<xref ref-type="bibr" rid="B180-ijms-19-01212">180</xref>,<xref ref-type="bibr" rid="B181-ijms-19-01212">181</xref>]. </p>
<p>Per1 and Per2 control CRs cells and modulate cell-related genes expression, such as c-Myc, to sustain the normal cell cycle [<xref ref-type="bibr" rid="B216-ijms-19-01212">216</xref>,<xref ref-type="bibr" rid="B217-ijms-19-01212">217</xref>]. mRNAs and proteins levels of circadian genes oscillate throughout the 24-hour period [<xref ref-type="bibr" rid="B180-ijms-19-01212">180</xref>]. </p>
</sec>
<sec id="sec7dot4-ijms-19-01212">
<title>7.4. Action of PPARγ on Circadian Rhythms</title>
<p>PPARγ directly acts with the core clock genes and presents diurnal fluctuations in liver and blood vessels [<xref ref-type="bibr" rid="B33-ijms-19-01212">33</xref>,<xref ref-type="bibr" rid="B218-ijms-19-01212">218</xref>]. In mice, impaired diurnal rhythms are induced by a knockdown of PPARγ [<xref ref-type="bibr" rid="B219-ijms-19-01212">219</xref>]. PPARγ agonists can regulate Bmal1 and the constitution of the heterodimer Clock/Bmal1 [<xref ref-type="bibr" rid="B33-ijms-19-01212">33</xref>,<xref ref-type="bibr" rid="B220-ijms-19-01212">220</xref>] and can then target Rev-Erb [<xref ref-type="bibr" rid="B221-ijms-19-01212">221</xref>] (<xref ref-type="fig" rid="ijms-19-01212-f004">Figure 4</xref>). Decrease of the clock-controlled gene Nocturin inhibits PPARγ oscillations in the liver of mice fed on high-fat diet. In normal circumstances, nocturin binds to PPARγ to enhance its transcriptional activity [<xref ref-type="bibr" rid="B222-ijms-19-01212">222</xref>]. The inhibtion of PPARγ expression prevents circadian function of 15-Deoxy-D 12,14-prostaglandin J2 (15-PGJ2) [<xref ref-type="bibr" rid="B219-ijms-19-01212">219</xref>]. The partner of PPARγ, RXR, interacts with Clock protein in a ligand-dependent manner and then decreases the formation and transcriptional activity of the Clock/Bmal1 heterodimer [<xref ref-type="bibr" rid="B223-ijms-19-01212">223</xref>]. PPARγ acts on the mammalian clock and energy metabolism [<xref ref-type="bibr" rid="B223-ijms-19-01212">223</xref>]. Circadian metabolism is directly regulated by PPARγ [<xref ref-type="bibr" rid="B219-ijms-19-01212">219</xref>]. Retinoic acid receptor-related orphan receptor γ t (RORγt) is considered as a key transcriptional factor for Th17 differentiation [<xref ref-type="bibr" rid="B224-ijms-19-01212">224</xref>,<xref ref-type="bibr" rid="B225-ijms-19-01212">225</xref>]. PPARγ can influence the function of Th cell clones [<xref ref-type="bibr" rid="B226-ijms-19-01212">226</xref>]. PPARγ agonists inhibit Th17 differentiation through the inhibition of RORγt induction [<xref ref-type="bibr" rid="B129-ijms-19-01212">129</xref>,<xref ref-type="bibr" rid="B227-ijms-19-01212">227</xref>,<xref ref-type="bibr" rid="B228-ijms-19-01212">228</xref>]. CD4<sup>+</sup> T cells fail to express RORγt under the action of PPARγ agonists [<xref ref-type="bibr" rid="B129-ijms-19-01212">129</xref>].</p>
</sec>
<sec id="sec7dot5-ijms-19-01212">
<title>7.5. Interest of Cortisol in MS</title>
<p>Cortisol production by the HPA axis (hypothalamic-pituitary-adrenal axis) during the acute phase of MS leads to suppression of T cell secretion of inflammatory factors, such as cytokines [<xref ref-type="bibr" rid="B229-ijms-19-01212">229</xref>]. The peak of inflammatory factor production occurs in association with low levels of cortisol. TNF-α and IL-6 production during active phases is consistent with reduction of night-time cortisol production [<xref ref-type="bibr" rid="B230-ijms-19-01212">230</xref>]. Cortisol production is regulated by circadian rhythms that present an elevated morning level, but normalizes by the evening in MS patients [<xref ref-type="bibr" rid="B231-ijms-19-01212">231</xref>]. However, the role of cortisol in MS remains unclear [<xref ref-type="bibr" rid="B183-ijms-19-01212">183</xref>]. HPA axis seems to be activated in relapsing-remitting MS patients but this phenomenon has not been shown in all studies [<xref ref-type="bibr" rid="B232-ijms-19-01212">232</xref>,<xref ref-type="bibr" rid="B233-ijms-19-01212">233</xref>]. Nevertheless, a normal cortisol level is associated with a more severe disease course [<xref ref-type="bibr" rid="B234-ijms-19-01212">234</xref>]. Rat strains with low HPA axis activity present worse EAE in comparison to rat strains with low HPA axis activity [<xref ref-type="bibr" rid="B235-ijms-19-01212">235</xref>]. These results suggest that elevated levels of cortisol suppress inflammation in MS even if other studies have shown that over-active HPA axis in association with high serum cortisol contributed to worse forms of MS [<xref ref-type="bibr" rid="B236-ijms-19-01212">236</xref>]. Cortisol seems not to act alone, and corticosteroids present in the CNS and blood may have an impact on the immune response. Corticosteroid concentration in cerebrospinal fluid present high levels in MS patients with stable disease and low levels with worse forms despite similar serum cortisol level [<xref ref-type="bibr" rid="B237-ijms-19-01212">237</xref>]. High serum cortisol level can inhibit inflammation process through an over-active HPA axis leading to protection in MS whereas disruption of HPA axis is associated with worse forms of the disease. Cortisol is known to have immunosuppressive effects by affecting cytokine secretion and T cell activation [<xref ref-type="bibr" rid="B238-ijms-19-01212">238</xref>]. Glucocorticoids are not limited to the inhibition of T cell response but also affect the decrease of macrophages, B cells and dendritic cells [<xref ref-type="bibr" rid="B239-ijms-19-01212">239</xref>]. Glucocorticoids in MS present many beneficial effects but the resistance observed in humans may complicate its use [<xref ref-type="bibr" rid="B240-ijms-19-01212">240</xref>]. Nevertheless, cortisol can affect CRs by glucocorticoid receptors [by activating the transcription of Per1 and Per2 [<xref ref-type="bibr" rid="B241-ijms-19-01212">241</xref>,<xref ref-type="bibr" rid="B242-ijms-19-01212">242</xref>]. In MS, the circadian oscillations of cortisol levels show that cortisol may have a key role in the regulation of peripheral clocks. In MS, no study has shown a link between PPARγ expression and cortisol level. Few studies have observed that high PPARγ agonists can increase cortisol levels in cancers [<xref ref-type="bibr" rid="B243-ijms-19-01212">243</xref>]. </p>
</sec>
<sec id="sec7dot6-ijms-19-01212">
<title>7.6. Interest of Melatonin in MS</title>
<p>Melatonin (also named 5-methoxy-<italic>N</italic>-acetyltryptamine) is a secreted by the pineal gland [<xref ref-type="bibr" rid="B244-ijms-19-01212">244</xref>]. Melatonin is released during darkness and thereby regulates the circadian regulation of sleep [<xref ref-type="bibr" rid="B245-ijms-19-01212">245</xref>,<xref ref-type="bibr" rid="B246-ijms-19-01212">246</xref>]. An inverse correlation is observed between melatonin levels and MS progression [<xref ref-type="bibr" rid="B247-ijms-19-01212">247</xref>,<xref ref-type="bibr" rid="B248-ijms-19-01212">248</xref>]. Melatonin has anti-inflammatory, anti-oxidant and neuroprotective effects [<xref ref-type="bibr" rid="B245-ijms-19-01212">245</xref>,<xref ref-type="bibr" rid="B249-ijms-19-01212">249</xref>,<xref ref-type="bibr" rid="B250-ijms-19-01212">250</xref>,<xref ref-type="bibr" rid="B251-ijms-19-01212">251</xref>,<xref ref-type="bibr" rid="B252-ijms-19-01212">252</xref>,<xref ref-type="bibr" rid="B253-ijms-19-01212">253</xref>]. Administration of melatonin reduces EAE severity through the suppression of Th17 cell number [<xref ref-type="bibr" rid="B202-ijms-19-01212">202</xref>,<xref ref-type="bibr" rid="B254-ijms-19-01212">254</xref>]. Moreover, CRs could be related to inflammation by affecting immunization [<xref ref-type="bibr" rid="B255-ijms-19-01212">255</xref>]. TNF-α and IL-1β overexpression can inhibit the melatonin synthesis pathway [<xref ref-type="bibr" rid="B256-ijms-19-01212">256</xref>,<xref ref-type="bibr" rid="B257-ijms-19-01212">257</xref>,<xref ref-type="bibr" rid="B258-ijms-19-01212">258</xref>]. TNF-α directly inhibits melatonin expression [<xref ref-type="bibr" rid="B259-ijms-19-01212">259</xref>]. Melatonin ameliorates EAE development by suppressing Th17 cells generation [<xref ref-type="bibr" rid="B202-ijms-19-01212">202</xref>,<xref ref-type="bibr" rid="B254-ijms-19-01212">254</xref>,<xref ref-type="bibr" rid="B260-ijms-19-01212">260</xref>,<xref ref-type="bibr" rid="B261-ijms-19-01212">261</xref>,<xref ref-type="bibr" rid="B262-ijms-19-01212">262</xref>]. Melatonin also ameliorates symptoms in EAE mouse models [<xref ref-type="bibr" rid="B202-ijms-19-01212">202</xref>,<xref ref-type="bibr" rid="B254-ijms-19-01212">254</xref>,<xref ref-type="bibr" rid="B260-ijms-19-01212">260</xref>,<xref ref-type="bibr" rid="B261-ijms-19-01212">261</xref>,<xref ref-type="bibr" rid="B262-ijms-19-01212">262</xref>] through the inhibition of Rev-Erb and ROR expressions, and by limiting Th17 cell differentiation and function [<xref ref-type="bibr" rid="B206-ijms-19-01212">206</xref>,<xref ref-type="bibr" rid="B260-ijms-19-01212">260</xref>]. Melatonin decreases phosphorylation of GSK-3β [<xref ref-type="bibr" rid="B263-ijms-19-01212">263</xref>,<xref ref-type="bibr" rid="B264-ijms-19-01212">264</xref>]. PPARγ agonists can upregulate melatonin levels to restore mitochondrial membrane potential, stimulate the biogenesis of mitochondria [<xref ref-type="bibr" rid="B265-ijms-19-01212">265</xref>] and enhance mitochondrial function [<xref ref-type="bibr" rid="B266-ijms-19-01212">266</xref>]. </p>
</sec>
</sec>
<sec id="sec8-ijms-19-01212">
<title>8. Conclusions</title>
<p>Demyelination during MS lesions is associated with reprogramming energy metabolism through the dysregulation of the opposed interplay of PPARγ and the WNT/β-catenin pathway (<xref ref-type="table" rid="ijms-19-01212-t001">Table 1</xref>). The canonical WNT/β-catenin pathway is upregulated by chronic neuroinflammation, whereas PPARγ is downregulated during demyelinating processes. These two systems act in an opposed and reverse manner. Demyelinating processes are associated with the increase of the WNT/β-catenin pathway and dysregulation of the circadian clock genes. In MS, over-activation of Bmal1 leads to stimulation of the canonical WNT/β-catenin pathway. Then, activation of the WNT/β-catenin pathway results in stimulation of glycolytic enzymes leading to activation of aerobic glycolysis. Lactate production induces dysfunction of CD4<sup>+</sup> T cells leading to axonal and neuronal damage during the MS demyelinating processes. PPARγ agonists can inhibit Th17 differentiation in CD4<sup>+</sup> T cells and can diminish cytokine release. In parallel, PPARγ agonists can interfere with reprogramming energy metabolism by directly inhibiting the WNT/β-catenin pathway and interacting with clock genes and thus, could be a promising therapeutic pathway in MS due to their interactions (<xref ref-type="fig" rid="ijms-19-01212-f005">Figure 5</xref>). These findings support the possibility of targeting these pathways with the goal of improving the symptoms of MS. Clinical trials and studies are needed to confirm this hypothesis in MS pathogenesis.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Alexandre Vallée, Yves Lecarpentier, Rémy Guillevin and Jean-Noël Vallée have contributed to this review. Alexandre Vallée, Yves Lecarpentier, Rémy Guillevin and Jean-Noël Vallée read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare that they have no competing interests.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Acetyl-coA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Acetyl-coenzyme A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">APC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Adenomatous polyposis coli</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Bmal1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Clock</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Circadian locomotor output cycles kaput</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cry</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cryptochrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CRs</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Circadian rhythms</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DSH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Disheveled</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FZD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Frizzled</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Glut</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Glucose transporter</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GSK-3β</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Glycogen synthase kinase-3β</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LDH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Lactate dehydrogenase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LRP 5/6</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Low-density lipoprotein receptor-related protein 5/6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MCT-1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Monocarboxylate lactate transporter-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Per</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Period</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPARγ</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Peroxisome proliferator-activated receptor γ</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PI3K-Akt</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol 3-kinase-protein kinase B</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PDH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pyruvate dehydrogenase complex</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PDK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pyruvate dehydrogenase kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RORs</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Retinoid-related orphan receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TCF/LEF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">T-cell factor/lymphoid enhancer factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TCA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Tricarboxylic acid</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-19-01212">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goverman</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Autoimmune T cell responses in the central nervous system</article-title>
<source/>Nat. Rev. Immunol.
          <year>2009</year>
<volume>9</volume>
<fpage>393</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="doi">10.1038/nri2550</pub-id>
<pub-id pub-id-type="pmid">19444307</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-19-01212">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trapp</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Nave</surname>
<given-names>K.-A.</given-names>
</name>
</person-group>
<article-title>Multiple sclerosis: An immune or neurodegenerative disorder?</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2008</year>
<volume>31</volume>
<fpage>247</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.30.051606.094313</pub-id>
<pub-id pub-id-type="pmid">18558855</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-19-01212">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasmussen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kivisäkk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Imitola</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Khoury</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing—Remitting experimental autoimmune encephalomyelitis</article-title>
<source/>Brain J. Neurol.
          <year>2007</year>
<volume>130</volume>
<fpage>2816</fpage>
<lpage>2829</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awm219</pub-id>
<pub-id pub-id-type="pmid">17890734</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-19-01212">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jadidi-Niaragh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mirshafiey</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Th17 cell, the new player of neuroinflammatory process in multiple sclerosis</article-title>
<source/>Scand. J. Immunol.
          <year>2011</year>
<volume>74</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-3083.2011.02536.x</pub-id>
<pub-id pub-id-type="pmid">21338381</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-19-01212">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Didonna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Oksenberg</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Genetic determinants of risk and progression in multiple sclerosis</article-title>
<source/>Clin. Chim. Acta Int. J. Clin. Chem.
          <year>2015</year>
<volume>449</volume>
<fpage>16</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.cca.2015.01.034</pub-id>
<pub-id pub-id-type="pmid">25661088</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-19-01212">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tourtellotte</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Rudick</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trapp</surname>
<given-names>B.D.</given-names>
</name>
</person-group>
<article-title>Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis</article-title>
<source/>N. Engl. J. Med.
          <year>2002</year>
<volume>346</volume>
<fpage>165</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa010994</pub-id>
<pub-id pub-id-type="pmid">11796850</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-19-01212">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franklin</surname>
<given-names>R.J.M.</given-names>
</name>
</person-group>
<article-title>Why does remyelination fail in multiple sclerosis?</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2002</year>
<volume>3</volume>
<fpage>705</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="doi">10.1038/nrn917</pub-id>
<pub-id pub-id-type="pmid">12209119</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-19-01212">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khwaja</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Volpe</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Pathogenesis of cerebral white matter injury of prematurity</article-title>
<source/>Arch. Dis. Child. Fetal Neonatal Ed.
          <year>2008</year>
<volume>93</volume>
<fpage>F153</fpage>
<lpage>F161</lpage>
<pub-id pub-id-type="doi">10.1136/adc.2006.108837</pub-id>
<pub-id pub-id-type="pmid">18296574</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-19-01212">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodward</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Inder</surname>
<given-names>T.E.</given-names>
</name>
</person-group>
<article-title>Neonatal MRI to predict neurodevelopmental outcomes in preterm infants</article-title>
<source/>N. Engl. J. Med.
          <year>2006</year>
<volume>355</volume>
<fpage>685</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa053792</pub-id>
<pub-id pub-id-type="pmid">16914704</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-19-01212">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Back</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Pathophysiology of glia in perinatal white matter injury</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>1790</fpage>
<lpage>1815</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22658</pub-id>
<pub-id pub-id-type="pmid">24687630</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-19-01212">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Billiards</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Haynes</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Folkerth</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Borenstein</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Trachtenberg</surname>
<given-names>F.L.</given-names>
</name>
<name>
<surname>Rowitch</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Ligon</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Volpe</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Kinney</surname>
<given-names>H.C.</given-names>
</name>
</person-group>
<article-title>Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia</article-title>
<source/>Brain Pathol.
          <year>2008</year>
<volume>18</volume>
<fpage>153</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1111/j.1750-3639.2007.00107.x</pub-id>
<pub-id pub-id-type="pmid">18177464</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-19-01212">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buser</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Maire</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Riddle</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Struve</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>L.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Arrested preoligodendrocyte maturation contributes to myelination failure in premature infants</article-title>
<source/>Ann. Neurol.
          <year>2012</year>
<volume>71</volume>
<fpage>93</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1002/ana.22627</pub-id>
<pub-id pub-id-type="pmid">22275256</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-19-01212">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fancy</surname>
<given-names>S.P.J.</given-names>
</name>
<name>
<surname>Kotter</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rowitch</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>R.J.M.</given-names>
</name>
</person-group>
<article-title>Overcoming remyelination failure in multiple sclerosis and other myelin disorders</article-title>
<source/>Exp. Neurol.
          <year>2010</year>
<volume>225</volume>
<fpage>18</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2009.12.020</pub-id>
<pub-id pub-id-type="pmid">20044992</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-19-01212">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhlmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miron</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Cuo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wegner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Antel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brück</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis</article-title>
<source/>Brain J. Neurol.
          <year>2008</year>
<volume>131</volume>
<fpage>1749</fpage>
<lpage>1758</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awn096</pub-id>
<pub-id pub-id-type="pmid">18515322</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-19-01212">
<label>15.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sandler</surname>
<given-names>S.</given-names>
</name>
</person-group>
<source/>Chemical and Engineering Thermodynamics
          <edition>4th ed.</edition>
<publisher-name>Wiely</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>2006</year>
</element-citation>
</ref>
<ref id="B16-ijms-19-01212">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Kondev</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Orme</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Theriot</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Thermodynamics of biological processes</article-title>
<source/>Methods Enzymol.
          <year>2011</year>
<volume>492</volume>
<fpage>27</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-381268-1.00014-8</pub-id>
<pub-id pub-id-type="pmid">21333788</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-19-01212">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Duthoit</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>J.-L.</given-names>
</name>
</person-group>
<article-title>Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction</article-title>
<source/>Front. Physiol.
          <year>2014</year>
<volume>5</volume>
<fpage>429</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00429</pub-id>
<pub-id pub-id-type="pmid">25414671</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-19-01212">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis</article-title>
<source/>Cell. Mol. Neurobiol.
          <year>2017</year>
<volume>38</volume>
<fpage>783</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1007/s10571-017-0550-9</pub-id>
<pub-id pub-id-type="pmid">28905149</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-19-01212">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsentidis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gourgiotis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kossiva</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marmarinos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doulgeraki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Karavanaki</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density</article-title>
<source/>Osteoporos. Int.
          <year>2017</year>
<volume>28</volume>
<fpage>945</fpage>
<lpage>953</lpage>
<pub-id pub-id-type="doi">10.1007/s00198-016-3802-5</pub-id>
<pub-id pub-id-type="pmid">27766367</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-19-01212">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pörksen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Danne</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kocova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castaño</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pociot</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ekstrøm</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Gammeltoft</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hvidøre Study Group on Childhood Diabetes Variation within the PPARG gene is associated with residual beta-cell function and glycemic control in children and adolescents during the first year of clinical type 1 diabetes</article-title>
<source/>Pediatr. Diabetes
          <year>2008</year>
<volume>9</volume>
<fpage>297</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-5448.2008.00398.x</pub-id>
<pub-id pub-id-type="pmid">18466209</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-19-01212">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrari</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Fallahi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vita</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Antonelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benvenga</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Peroxisome Proliferator-Activated Receptor-γ in Thyroid Autoimmunity</article-title>
<source/>PPAR Res.
          <year>2015</year>
<volume>2015</volume>
<fpage>232818</fpage>
<pub-id pub-id-type="doi">10.1155/2015/232818</pub-id>
<pub-id pub-id-type="pmid">25722716</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-19-01212">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ayala-Haedo</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Field</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Pelaez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wester</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>RNA-Sequencing Gene Expression Profiling of Orbital Adipose-Derived Stem Cell Population Implicate HOX Genes and WNT Signaling Dysregulation in the Pathogenesis of Thyroid-Associated Orbitopathy</article-title>
<source/>Investig. Ophthalmol. Vis. Sci.
          <year>2017</year>
<volume>58</volume>
<fpage>6146</fpage>
<lpage>6158</lpage>
<pub-id pub-id-type="doi">10.1167/iovs.17-22237</pub-id>
<pub-id pub-id-type="pmid">29214313</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-19-01212">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.F.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.Q.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>D.Z.</given-names>
</name>
</person-group>
<article-title>Expression of β-catenin in rheumatoid arthritis fibroblast-like synoviocytes</article-title>
<source/>Scand. J. Rheumatol.
          <year>2011</year>
<volume>40</volume>
<fpage>26</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.3109/03009742.2010.486767</pub-id>
<pub-id pub-id-type="pmid">20840015</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-19-01212">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marder</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Khalatbari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Myles</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Hench</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lustig</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yalavarthi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Parameswaran</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brook</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis</article-title>
<source/>J. Am. Heart Assoc.
          <year>2013</year>
<volume>2</volume>
<fpage>e000441</fpage>
<pub-id pub-id-type="doi">10.1161/JAHA.113.000441</pub-id>
<pub-id pub-id-type="pmid">24252844</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-19-01212">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Krokidis</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pineau</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Quillard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cortes-Morichetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coirault</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Increased entropy production in diaphragm muscle of PPAR alpha knockout mice</article-title>
<source/>J. Theor. Biol.
          <year>2008</year>
<volume>250</volume>
<fpage>92</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1016/j.jtbi.2007.09.022</pub-id>
<pub-id pub-id-type="pmid">17980390</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-19-01212">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rone</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Q.-L.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.-C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bedard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Almazan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ludwin</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival</article-title>
<source/>J. Neurosci. Off. J. Soc. Neurosci.
          <year>2016</year>
<volume>36</volume>
<fpage>4698</fpage>
<lpage>4707</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4077-15.2016</pub-id>
<pub-id pub-id-type="pmid">27122029</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-19-01212">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Wnt meets Warburg: Another piece in the puzzle?</article-title>
<source/>EMBO J.
          <year>2014</year>
<volume>33</volume>
<fpage>1420</fpage>
<lpage>1422</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201488785</pub-id>
<pub-id pub-id-type="pmid">24843042</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-19-01212">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>On the origin of cancer cells</article-title>
<source/>Science
          <year>1956</year>
<volume>123</volume>
<fpage>309</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id>
<pub-id pub-id-type="pmid">13298683</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-19-01212">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.-T.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brewer</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L)</article-title>
<source/>Cancer Biol. Ther.
          <year>2010</year>
<volume>9</volume>
<fpage>122</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.9.2.10379</pub-id>
<pub-id pub-id-type="pmid">19923925</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-19-01212">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfeiffer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Schuster</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonhoeffer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cooperation and competition in the evolution of ATP-producing pathways</article-title>
<source/>Science
          <year>2001</year>
<volume>292</volume>
<fpage>504</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1126/science.1058079</pub-id>
<pub-id pub-id-type="pmid">11283355</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-19-01212">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Involvement of the Warburg effect in non-tumor diseases processes</article-title>
<source/>J. Cell. Physiol.
          <year>2018</year>
<volume>233</volume>
<fpage>2839</fpage>
<lpage>2849</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.25998</pub-id>
<pub-id pub-id-type="pmid">28488732</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-19-01212">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newland</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Starkweather</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sorenson</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Central fatigue in multiple sclerosis: A review of the literature</article-title>
<source/>J. Spinal Cord Med.
          <year>2016</year>
<volume>39</volume>
<fpage>386</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1080/10790268.2016.1168587</pub-id>
<pub-id pub-id-type="pmid">27146427</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-19-01212">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aoyagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Soodvilai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Symons</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Schnermann</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Litwin</surname>
<given-names>S.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1</article-title>
<source/>Cell Metab.
          <year>2008</year>
<volume>8</volume>
<fpage>482</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2008.10.009</pub-id>
<pub-id pub-id-type="pmid">19041764</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-19-01212">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Thermodynamics in Neurodegenerative Diseases: Interplay between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms</article-title>
<source/>Neuromolecular Med.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1007/s12017-018-8486-x</pub-id>
<pub-id pub-id-type="pmid">29572723</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-19-01212">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Matter</surname>
<given-names>E.K.</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>A role for central nervous system PPAR-γ in the regulation of energy balance</article-title>
<source/>Nat. Med.
          <year>2011</year>
<volume>17</volume>
<fpage>623</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2349</pub-id>
<pub-id pub-id-type="pmid">21532595</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-19-01212">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bookout</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Mangelsdorf</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>789</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.06.049</pub-id>
<pub-id pub-id-type="pmid">16923397</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-19-01212">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalik</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Grimaldi</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Kadowaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>O’Rahilly</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors</article-title>
<source/>Pharmacol. Rev.
          <year>2006</year>
<volume>58</volume>
<fpage>726</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="doi">10.1124/pr.58.4.5</pub-id>
<pub-id pub-id-type="pmid">17132851</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-19-01212">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blandon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rude</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elfar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>PPAR-γ agonist in treatment of diabetes: Cardiovascular safety considerations</article-title>
<source/>Cardiovasc. Hematol. Agents Med. Chem.
          <year>2012</year>
<volume>10</volume>
<fpage>124</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.2174/187152512800388948</pub-id>
<pub-id pub-id-type="pmid">22471957</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-19-01212">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oyekan</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>PPARs and their effects on the cardiovascular system</article-title>
<source/>Clin. Exp. Hypertens.
          <year>2011</year>
<volume>33</volume>
<fpage>287</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.3109/10641963.2010.531845</pub-id>
<pub-id pub-id-type="pmid">21721973</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-19-01212">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montague</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Prins</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Holder</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Digby</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Sewter</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>V.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation</article-title>
<source/>J. Clin. Investig.
          <year>1997</year>
<volume>100</volume>
<fpage>3149</fpage>
<lpage>3153</lpage>
<pub-id pub-id-type="doi">10.1172/JCI119870</pub-id>
<pub-id pub-id-type="pmid">9399962</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-19-01212">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricote</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Willson</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
</person-group>
<article-title>The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation</article-title>
<source/>Nature
          <year>1998</year>
<volume>391</volume>
<fpage>79</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1038/34178</pub-id>
<pub-id pub-id-type="pmid">9422508</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-19-01212">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asakawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Uozumi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kadowaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Komuro</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo</article-title>
<source/>Circulation
          <year>2002</year>
<volume>105</volume>
<fpage>1240</fpage>
<lpage>1246</lpage>
<pub-id pub-id-type="doi">10.1161/hc1002.105225</pub-id>
<pub-id pub-id-type="pmid">11889020</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-19-01212">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miriyala</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Panchatcharam</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>PPARγ and Its Role in Cardiovascular Diseases</article-title>
<source/>PPAR Res.
          <year>2017</year>
<volume>2017</volume>
<fpage>6404638</fpage>
<pub-id pub-id-type="doi">10.1155/2017/6404638</pub-id>
<pub-id pub-id-type="pmid">28243251</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-19-01212">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moriya</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yamakawa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kanda</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: Are the reagents beneficial or harmful?</article-title>
<source/>Int. J. Cardiol.
          <year>2008</year>
<volume>130</volume>
<fpage>131</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2008.03.080</pub-id>
<pub-id pub-id-type="pmid">18582964</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-19-01212">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polvani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tarocchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>PPARγ and Oxidative Stress: Con(β) Catenating NRF2 and FOXO</article-title>
<source/>PPAR Res.
          <year>2012</year>
<volume>2012</volume>
<fpage>641087</fpage>
<pub-id pub-id-type="doi">10.1155/2012/641087</pub-id>
<pub-id pub-id-type="pmid">22481913</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-19-01212">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braissant</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Foufelle</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scotto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dauça</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wahli</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat</article-title>
<source/>Endocrinology
          <year>1996</year>
<volume>137</volume>
<fpage>354</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1210/endo.137.1.8536636</pub-id>
<pub-id pub-id-type="pmid">8536636</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-19-01212">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Minghetti</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists</article-title>
<source/>PPAR Res.
          <year>2008</year>
<volume>2008</volume>
<fpage>864140</fpage>
<pub-id pub-id-type="doi">10.1155/2008/864140</pub-id>
<pub-id pub-id-type="pmid">18464925</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-19-01212">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lovett-Racke</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Racke</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs</article-title>
<source/>PPAR Res.
          <year>2010</year>
<volume>2010</volume>
<fpage>104705</fpage>
<pub-id pub-id-type="doi">10.1155/2010/104705</pub-id>
<pub-id pub-id-type="pmid">21234105</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-19-01212">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dani</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>von Oppen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dolf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Endl</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Klockgether</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Engelhardt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Knolle</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Brain endothelial PPARgamma controls inflammation-induced CD4<sup>+</sup> T cell adhesion and transmigration in vitro</article-title>
<source/>J. Neuroimmunol.
          <year>2007</year>
<volume>190</volume>
<fpage>34</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.07.017</pub-id>
<pub-id pub-id-type="pmid">17719655</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-19-01212">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricote</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
</person-group>
<article-title>PPARs and molecular mechanisms of transrepression</article-title>
<source/>Biochim. Biophys. Acta
          <year>2007</year>
<volume>1771</volume>
<fpage>926</fpage>
<lpage>935</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbalip.2007.02.013</pub-id>
<pub-id pub-id-type="pmid">17433773</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-19-01212">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Touyz</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Schiffrin</surname>
<given-names>E.L.</given-names>
</name>
</person-group>
<article-title>Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells</article-title>
<source/>Hypertens.
          <year>1999</year>
<volume>34</volume>
<fpage>976</fpage>
<lpage>982</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.34.4.976</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-19-01212">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Széles</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Töröcsik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>PPARgamma in immunity and inflammation: Cell types and diseases</article-title>
<source/>Biochim. Biophys. Acta
          <year>2007</year>
<volume>1771</volume>
<fpage>1014</fpage>
<lpage>1030</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbalip.2007.02.005</pub-id>
<pub-id pub-id-type="pmid">17418635</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-19-01212">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McIntyre</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Pontsler</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>St Hilaire</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hinshaw</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2003</year>
<volume>100</volume>
<fpage>131</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0135855100</pub-id>
<pub-id pub-id-type="pmid">12502787</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-19-01212">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Papkoff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scambler</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shackleford</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Varmus</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>A new nomenclature for int-1 and related genes: The Wnt gene family</article-title>
<source/>Cell
          <year>1991</year>
<volume>64</volume>
<fpage>231</fpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(91)90633-A</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-19-01212">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacDonald</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Tamai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Wnt/beta-catenin signaling: Components, mechanisms, and diseases</article-title>
<source/>Dev. Cell
          <year>2009</year>
<volume>17</volume>
<fpage>9</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id>
<pub-id pub-id-type="pmid">19619488</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-19-01212">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities</article-title>
<source/>Cell
          <year>2017</year>
<volume>169</volume>
<fpage>985</fpage>
<lpage>999</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id>
<pub-id pub-id-type="pmid">28575679</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-19-01212">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Wnt signaling</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2012</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.1101/cshperspect.a011163</pub-id>
<pub-id pub-id-type="pmid">22550232</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-19-01212">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Semenov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tamai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: Arrows point the way</article-title>
<source/>Dev. Camb. Engl.
          <year>2004</year>
<volume>131</volume>
<fpage>1663</fpage>
<lpage>1677</lpage>
<pub-id pub-id-type="doi">10.1242/dev.01117</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-19-01212">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Hocking</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca<sup>2+</sup> pathways</article-title>
<source/>Oncogene
          <year>1999</year>
<volume>18</volume>
<fpage>7860</fpage>
<lpage>7872</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1203245</pub-id>
<pub-id pub-id-type="pmid">10630639</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-19-01212">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Wnt signalling in stem cells and cancer</article-title>
<source/>Nature
          <year>2005</year>
<volume>434</volume>
<fpage>843</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="doi">10.1038/nature03319</pub-id>
<pub-id pub-id-type="pmid">15829953</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-19-01212">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anastas</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>WNT signalling pathways as therapeutic targets in cancer</article-title>
<source/>Nat. Rev. Cancer
          <year>2013</year>
<volume>13</volume>
<fpage>11</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1038/nrc3419</pub-id>
<pub-id pub-id-type="pmid">23258168</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-19-01212">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jho</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Wnt/β-catenin signalling: From plasma membrane to nucleus</article-title>
<source/>Biochem. J.
          <year>2013</year>
<volume>450</volume>
<fpage>9</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20121284</pub-id>
<pub-id pub-id-type="pmid">23343194</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-19-01212">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Kühl</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>An updated overview on Wnt signaling pathways: A prelude for more</article-title>
<source/>Circ. Res.
          <year>2010</year>
<volume>106</volume>
<fpage>1798</fpage>
<lpage>1806</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.219840</pub-id>
<pub-id pub-id-type="pmid">20576942</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-19-01212">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Taketo</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Adenomatous polyposis coli (APC): A multi-functional tumor suppressor gene</article-title>
<source/>J. Cell Sci.
          <year>2007</year>
<volume>120</volume>
<fpage>3327</fpage>
<lpage>3335</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.03485</pub-id>
<pub-id pub-id-type="pmid">17881494</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-19-01212">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komiya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Habas</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Wnt signal transduction pathways</article-title>
<source/>Organogenesis
          <year>2008</year>
<volume>4</volume>
<fpage>68</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.4161/org.4.2.5851</pub-id>
<pub-id pub-id-type="pmid">19279717</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-19-01212">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Aguiar</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Naik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ostadsharif</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wencker</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sotoudeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Malekzadeh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sherwin</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans</article-title>
<source/>Cell Metab.
          <year>2013</year>
<volume>17</volume>
<fpage>197</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2013.01.009</pub-id>
<pub-id pub-id-type="pmid">23395167</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-19-01212">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>G.-W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iwakiri</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a</article-title>
<source/>FASEB J.
          <year>2015</year>
<volume>29</volume>
<fpage>3436</fpage>
<lpage>3445</lpage>
<pub-id pub-id-type="doi">10.1096/fj.15-271171</pub-id>
<pub-id pub-id-type="pmid">25917329</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-19-01212">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S.-J.</given-names>
</name>
</person-group>
<article-title>Wnt signaling in the pathogenesis of multiple sclerosis-associated chronic pain</article-title>
<source/>J. Neuroimmune Pharmacol.
          <year>2012</year>
<volume>7</volume>
<fpage>904</fpage>
<lpage>913</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-012-9370-3</pub-id>
<pub-id pub-id-type="pmid">22547300</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-19-01212">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaiser</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Stebbins</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Skias</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Jeffery</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Stefoski</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Katsamakis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis</article-title>
<source/>J. Neuroimmunol.
          <year>2009</year>
<volume>211</volume>
<fpage>124</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2009.04.011</pub-id>
<pub-id pub-id-type="pmid">19446890</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-19-01212">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Stebbins</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients</article-title>
<source/>Neurosci. Lett.
          <year>2010</year>
<volume>472</volume>
<fpage>153</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.01.046</pub-id>
<pub-id pub-id-type="pmid">20144689</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-19-01212">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sastre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Knolle</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Klockgether</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients</article-title>
<source/>J. Immunol. 1950
          <year>2005</year>
<volume>175</volume>
<fpage>4948</fpage>
<lpage>4955</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.175.8.4948</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-19-01212">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esmaeili</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Waggoner</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Deloach</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calingasan</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Kiaei</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo</article-title>
<source/>Hum. Mol. Genet.
          <year>2016</year>
<volume>25</volume>
<fpage>317</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv477</pub-id>
<pub-id pub-id-type="pmid">26604138</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-19-01212">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma</article-title>
<source/>Front. Physiol.
          <year>2017</year>
<volume>8</volume>
<fpage>352</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2017.00352</pub-id>
<pub-id pub-id-type="pmid">28620312</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-19-01212">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas</article-title>
<source/>Rev. Neurosci.
          <year>2018</year>
<volume>29</volume>
<fpage>71</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1515/revneuro-2017-0032</pub-id>
<pub-id pub-id-type="pmid">28822229</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-19-01212">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Opposite Interplay between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas</article-title>
<source/>Neurosci. Bull.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1007/s12264-018-0219-5</pub-id>
<pub-id pub-id-type="pmid">29582250</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-19-01212">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>J.-L.</given-names>
</name>
</person-group>
<article-title>Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer</article-title>
<source/>PPAR Res.
          <year>2017</year>
<volume>2017</volume>
<fpage>5879090</fpage>
<pub-id pub-id-type="doi">10.1155/2017/5879090</pub-id>
<pub-id pub-id-type="pmid">28298922</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-19-01212">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>J.-L.</given-names>
</name>
</person-group>
<article-title>Thermodynamics in cancers: Opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway</article-title>
<source/>Clin. Transl. Med.
          <year>2017</year>
<volume>6</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.1186/s40169-017-0144-7</pub-id>
<pub-id pub-id-type="pmid">28405929</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-19-01212">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>2537</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18122537</pub-id>
<pub-id pub-id-type="pmid">29186898</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-19-01212">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>90579</fpage>
<lpage>90604</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.21234</pub-id>
<pub-id pub-id-type="pmid">29163854</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-19-01212">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Schussler</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The Myofibroblast: TGFβ-1, A Conductor which Plays a Key Role in Fibrosis by Regulating the Balance between PPARγ and the Canonical WNT Pathway</article-title>
<source/>Nucl. Recept. Res.
          <year>2017</year>
<volume>23</volume>
<pub-id pub-id-type="doi">10.11131/2017/101299</pub-id>
<pub-id pub-id-type="pmid">29016360</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-19-01212">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease</article-title>
<source/>Acta Biochim. Biophys. Sin.
          <year>2017</year>
<volume>49</volume>
<fpage>853</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1093/abbs/gmx073</pub-id>
<pub-id pub-id-type="pmid">28981597</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-19-01212">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Reprogramming energetic metabolism in Alzheimer’s disease</article-title>
<source/>Life Sci.
          <year>2018</year>
<volume>193</volume>
<fpage>141</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2017.10.033</pub-id>
<pub-id pub-id-type="pmid">29079469</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-19-01212">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma</article-title>
<source/>Front. Neurosci.
          <year>2016</year>
<volume>10</volume>
<fpage>459</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00459</pub-id>
<pub-id pub-id-type="pmid">27807401</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-19-01212">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Aerobic Glycolysis Hypothesis Through WNT/Beta-Catenin Pathway in Exudative Age-Related Macular Degeneration</article-title>
<source/>J. Mol. Neurosci.
          <year>2017</year>
<volume>62</volume>
<fpage>368</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-017-0947-4</pub-id>
<pub-id pub-id-type="pmid">28689265</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-19-01212">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guillevin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>PPARγ agonists: Potential treatments for exudative age-related macular degeneration</article-title>
<source/>Life Sci.
          <year>2017</year>
<volume>188</volume>
<fpage>123</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2017.09.008</pub-id>
<pub-id pub-id-type="pmid">28887057</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-19-01212">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis</article-title>
<source/>Front. Neurol.
          <year>2016</year>
<volume>7</volume>
<fpage>100</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2016.00100</pub-id>
<pub-id pub-id-type="pmid">27445967</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-19-01212">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ajmone-Cat</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>D’Urso</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>di Blasio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Brignone</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>De Simone</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Minghetti</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells</article-title>
<source/>Brain. Behav. Immun.
          <year>2016</year>
<volume>55</volume>
<fpage>225</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2015.11.012</pub-id>
<pub-id pub-id-type="pmid">26593276</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-19-01212">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansson</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Are</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greicius</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>I.-C.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arulampalam</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pettersson</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2005</year>
<volume>102</volume>
<fpage>1460</fpage>
<lpage>1465</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0405928102</pub-id>
<pub-id pub-id-type="pmid">15665104</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-19-01212">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drygiannakis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Valatas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sfakianaki</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bourikas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Manousou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kambas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ritis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kolios</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kouroumalis</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: Implication in intestinal fibrosis</article-title>
<source/>J. Crohns Colitis
          <year>2013</year>
<volume>7</volume>
<fpage>286</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1016/j.crohns.2012.04.008</pub-id>
<pub-id pub-id-type="pmid">22578910</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-19-01212">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farmer</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Regulation of PPARgamma activity during adipogenesis</article-title>
<source/>Int. J. Obes.
          <year>2005</year>
<volume>29</volume>
<issue>Suppl. 1</issue>
<fpage>S13</fpage>
<lpage>S16</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ijo.0802907</pub-id>
<pub-id pub-id-type="pmid">15711576</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-19-01212">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname>
<given-names>K.-I.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Woeller</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Phipps</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Sime</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hindman</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Huxlin</surname>
<given-names>K.R.</given-names>
</name>
</person-group>
<article-title>Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation</article-title>
<source/>Am. J. Pathol.
          <year>2014</year>
<volume>184</volume>
<fpage>1429</fpage>
<lpage>1445</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2014.01.026</pub-id>
<pub-id pub-id-type="pmid">24650561</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-19-01212">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mundra</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mahato</surname>
<given-names>R.I.</given-names>
</name>
</person-group>
<article-title>Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis</article-title>
<source/>Pharm. Res.
          <year>2014</year>
<volume>31</volume>
<fpage>1158</fpage>
<lpage>1169</lpage>
<pub-id pub-id-type="doi">10.1007/s11095-013-1239-5</pub-id>
<pub-id pub-id-type="pmid">24249038</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-19-01212">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.-W.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.C.</given-names>
</name>
</person-group>
<article-title>Transcription factor Snail is a novel regulator of adipocyte differentiation via inhibiting the expression of peroxisome proliferator-activated receptor γ</article-title>
<source/>Cell. Mol. Life Sci.
          <year>2013</year>
<volume>70</volume>
<fpage>3959</fpage>
<lpage>3971</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-013-1363-8</pub-id>
<pub-id pub-id-type="pmid">23689589</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-19-01212">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The improving effects on hepatic fibrosis of interferon-γ liposomes targeted to hepatic stellate cells</article-title>
<source/>Nanotechnology
          <year>2012</year>
<volume>23</volume>
<fpage>265101</fpage>
<pub-id pub-id-type="doi">10.1088/0957-4484/23/26/265101</pub-id>
<pub-id pub-id-type="pmid">22700686</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-19-01212">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes</article-title>
<source/>J. Biol. Chem.
          <year>2004</year>
<volume>279</volume>
<fpage>45020</fpage>
<lpage>45027</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M407050200</pub-id>
<pub-id pub-id-type="pmid">15308623</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-19-01212">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>β-Catenin pathway is required for TGF-β1 inhibition of PPARγ expression in cultured hepatic stellate cells</article-title>
<source/>Pharmacol. Res.
          <year>2012</year>
<volume>66</volume>
<fpage>219</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2012.06.003</pub-id>
<pub-id pub-id-type="pmid">22706027</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-19-01212">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segel</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Izbicki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>P.Y.</given-names>
</name>
<name>
<surname>Or</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Wallach-Dayan</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Breuer</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis</article-title>
<source/>Am. J. Physiol. Lung Cell. Mol. Physiol.
          <year>2003</year>
<volume>285</volume>
<fpage>L1255</fpage>
<lpage>L1262</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.00303.2002</pub-id>
<pub-id pub-id-type="pmid">12857673</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-19-01212">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shim</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B.-W.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>M.-J.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>G.-R.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.-M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats</article-title>
<source/>J. Diabetes Investig.
          <year>2014</year>
<volume>5</volume>
<fpage>362</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1111/jdi.12153</pub-id>
<pub-id pub-id-type="pmid">25411595</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-19-01212">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pradeep</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway</article-title>
<source/>J. Biol. Chem.
          <year>2004</year>
<volume>279</volume>
<fpage>35583</fpage>
<lpage>35594</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M403143200</pub-id>
<pub-id pub-id-type="pmid">15190077</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-19-01212">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.-F.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.-M.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.-M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional role of PPAR-γ on the proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>12671</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-12570-6</pub-id>
<pub-id pub-id-type="pmid">28978936</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-19-01212">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Repression of beta-catenin signaling by PPAR gamma ligands</article-title>
<source/>Eur. J. Pharmacol.
          <year>2010</year>
<volume>636</volume>
<fpage>198</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2010.03.010</pub-id>
<pub-id pub-id-type="pmid">20303941</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-19-01212">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takada</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kouzmenko</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis</article-title>
<source/>Nat. Rev. Rheumatol.
          <year>2009</year>
<volume>5</volume>
<fpage>442</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.1038/nrrheum.2009.137</pub-id>
<pub-id pub-id-type="pmid">19581903</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-19-01212">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Gras</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Giocondo</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Willerson</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Khoury</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Marian</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy</article-title>
<source/>J. Clin. Investig.
          <year>2006</year>
<volume>116</volume>
<fpage>2012</fpage>
<lpage>2021</lpage>
<pub-id pub-id-type="doi">10.1172/JCI27751</pub-id>
<pub-id pub-id-type="pmid">16823493</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-19-01212">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbrecht</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cullinan</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leibowitz</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Moller</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>1996</year>
<volume>224</volume>
<fpage>431</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1996.1044</pub-id>
<pub-id pub-id-type="pmid">8702406</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-19-01212">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fajas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Auboeuf</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Raspé</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Schoonjans</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lefebvre</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Saladin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Najib</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Laville</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fruchart</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Deeb</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The organization, promoter analysis, and expression of the human PPARgamma gene</article-title>
<source/>J. Biol. Chem.
          <year>1997</year>
<volume>272</volume>
<fpage>18779</fpage>
<lpage>18789</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.272.30.18779</pub-id>
<pub-id pub-id-type="pmid">9228052</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-19-01212">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>B.-H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis</article-title>
<source/>Biochem. J.
          <year>2003</year>
<volume>376</volume>
<fpage>607</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1042/bj20030426</pub-id>
<pub-id pub-id-type="pmid">12954078</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-19-01212">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akinyeke</surname>
<given-names>T.O.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>L.V.</given-names>
</name>
</person-group>
<article-title>Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism</article-title>
<source/>Cancer Biol. Ther.
          <year>2011</year>
<volume>11</volume>
<fpage>1046</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="doi">10.4161/cbt.11.12.15709</pub-id>
<pub-id pub-id-type="pmid">21525782</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-19-01212">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gustafson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Eliasson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: A link with osteogenesis</article-title>
<source/>Diabetologia
          <year>2010</year>
<volume>53</volume>
<fpage>536</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-009-1615-1</pub-id>
<pub-id pub-id-type="pmid">19943155</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-19-01212">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.-S.</given-names>
</name>
</person-group>
<article-title>Wnt/β-catenin signaling plays a distinct role in methyl gallate-mediated inhibition of adipogenesis</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2016</year>
<volume>479</volume>
<fpage>22</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2016.08.178</pub-id>
<pub-id pub-id-type="pmid">27592552</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-19-01212">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nonaka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tsutsumi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sakakibara</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Naito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>T.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>COUP-TFII acts downstream of Wnt/beta-catenin signal to silence PPARgamma gene expression and repress adipogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>5819</fpage>
<lpage>5824</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0901676106</pub-id>
<pub-id pub-id-type="pmid">19307559</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-19-01212">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Daviaud</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pradère</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Grès</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guigné</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wabitsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saulnier-Blache</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2</article-title>
<source/>J. Biol. Chem.
          <year>2005</year>
<volume>280</volume>
<fpage>14656</fpage>
<lpage>14662</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M412585200</pub-id>
<pub-id pub-id-type="pmid">15710620</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-19-01212">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>J.T.M.</given-names>
</name>
<name>
<surname>McLennan</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>L.W.-Y.</given-names>
</name>
<name>
<surname>Bonner</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Twigg</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Connective tissue growth factor inhibits adipocyte differentiation</article-title>
<source/>Am. J. Physiol. Cell Physiol.
          <year>2008</year>
<volume>295</volume>
<fpage>C740</fpage>
<lpage>C751</lpage>
<pub-id pub-id-type="doi">10.1152/ajpcell.00333.2007</pub-id>
<pub-id pub-id-type="pmid">18596209</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-19-01212">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamasaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miyashita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Migita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Origuchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Eguchi</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells</article-title>
<source/>Rheumatology
          <year>2004</year>
<volume>43</volume>
<fpage>448</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="doi">10.1093/rheumatology/keh092</pub-id>
<pub-id pub-id-type="pmid">14734788</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-19-01212">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iwabuchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morohashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Onoé</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma</article-title>
<source/>J. Neuroimmunol.
          <year>2001</year>
<volume>116</volume>
<fpage>40</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-5728(01)00285-5</pub-id>
<pub-id pub-id-type="pmid">11311328</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-19-01212">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diab</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>R.Z.</given-names>
</name>
<name>
<surname>Phanavanh</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lovett-Racke</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Drew</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Racke</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis</article-title>
<source/>J. Immunol.
          <year>2002</year>
<volume>168</volume>
<fpage>2508</fpage>
<lpage>2515</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.168.5.2508</pub-id>
<pub-id pub-id-type="pmid">11859145</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-19-01212">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feinstein</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Galea</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gavrilyuk</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Brosnan</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Whitacre</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Dumitrescu-Ozimek</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Pershadsingh</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis</article-title>
<source/>Ann. Neurol.
          <year>2002</year>
<volume>51</volume>
<fpage>694</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1002/ana.10206</pub-id>
<pub-id pub-id-type="pmid">12112074</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-19-01212">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natarajan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bright</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation</article-title>
<source/>Genes Immun.
          <year>2002</year>
<volume>3</volume>
<fpage>59</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1038/sj.gene.6363832</pub-id>
<pub-id pub-id-type="pmid">11960303</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-19-01212">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulman</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Heyman</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: Intermolecular synergy requires only the PPARgamma hormone-dependent activation function</article-title>
<source/>Mol. Cell. Biol.
          <year>1998</year>
<volume>18</volume>
<fpage>3483</fpage>
<lpage>3494</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.18.6.3483</pub-id>
<pub-id pub-id-type="pmid">9584188</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-19-01212">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nolte</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Wisely</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>McInerney</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Milburn</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
</person-group>
<article-title>Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators</article-title>
<source/>Nature
          <year>1998</year>
<volume>395</volume>
<fpage>199</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1038/26040</pub-id>
<pub-id pub-id-type="pmid">9744281</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-19-01212">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Jarjour</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Oumesmar</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Kerninon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krezel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kagechika</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baron-Van Evercooren</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Retinoid X receptor gamma signaling accelerates CNS remyelination</article-title>
<source/>Nat. Neurosci.
          <year>2011</year>
<volume>14</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2702</pub-id>
<pub-id pub-id-type="pmid">21131950</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-19-01212">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedusi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Martorana</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maggi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The peroxisome proliferator-activated receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>35899</fpage>
<lpage>35911</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.366419</pub-id>
<pub-id pub-id-type="pmid">22910911</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-19-01212">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drew</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Storer</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chavis</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Hormone regulation of microglial cell activation: Relevance to multiple sclerosis</article-title>
<source/>Brain Res. Brain Res. Rev.
          <year>2005</year>
<volume>48</volume>
<fpage>322</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresrev.2004.12.020</pub-id>
<pub-id pub-id-type="pmid">15850670</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-19-01212">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drew</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Racke</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>PPAR-gamma: Therapeutic Potential for Multiple Sclerosis</article-title>
<source/>PPAR Res.
          <year>2008</year>
<volume>2008</volume>
<fpage>627463</fpage>
<pub-id pub-id-type="doi">10.1155/2008/627463</pub-id>
<pub-id pub-id-type="pmid">18604287</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-19-01212">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duvanel</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Honegger</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pershadsingh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Matthieu</surname>
<given-names>J.-M.</given-names>
</name>
</person-group>
<article-title>Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro</article-title>
<source/>J. Neurosci. Res.
          <year>2003</year>
<volume>71</volume>
<fpage>246</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.10471</pub-id>
<pub-id pub-id-type="pmid">12503087</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-19-01212">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luna-Medina</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cortes-Canteli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martínez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Perez-Castillo</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation</article-title>
<source/>J. Biol. Chem.
          <year>2005</year>
<volume>280</volume>
<fpage>21453</fpage>
<lpage>21462</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M414390200</pub-id>
<pub-id pub-id-type="pmid">15817469</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-19-01212">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paintlia</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Paintlia</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappaB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: Implication for CNS-demyelinating diseases</article-title>
<source/>J. Immunol.
          <year>2006</year>
<volume>176</volume>
<fpage>4385</fpage>
<lpage>4398</lpage>
<pub-id pub-id-type="pmid">16547277</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-19-01212">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Joers</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bondarenko</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Kemnitz</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Emborg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys</article-title>
<source/>J. Neuroinflamm.
          <year>2011</year>
<volume>8</volume>
<fpage>91</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-91</pub-id>
<pub-id pub-id-type="pmid">21819568</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-19-01212">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Bing</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt</article-title>
<source/>J. Neuroinflamm.
          <year>2008</year>
<volume>5</volume>
<fpage>4</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-5-4</pub-id>
<pub-id pub-id-type="pmid">18205920</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-19-01212">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Burgdorf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dani</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Saijo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Flossdorf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hucke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alferink</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity</article-title>
<source/>J. Exp. Med.
          <year>2009</year>
<volume>206</volume>
<fpage>2079</fpage>
<lpage>2089</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20082771</pub-id>
<pub-id pub-id-type="pmid">19737866</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-19-01212">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unoda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Doi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamane</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hosokawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hanafusa</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis</article-title>
<source/>J. Neuroimmunol.
          <year>2013</year>
<volume>256</volume>
<fpage>7</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2012.12.003</pub-id>
<pub-id pub-id-type="pmid">23276800</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-19-01212">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storer</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chavis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Drew</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis</article-title>
<source/>J. Neuroimmunol.
          <year>2005</year>
<volume>161</volume>
<fpage>113</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2004.12.015</pub-id>
<pub-id pub-id-type="pmid">15748950</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-19-01212">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Drew</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia</article-title>
<source/>J. Immunol.
          <year>2007</year>
<volume>178</volume>
<fpage>1904</fpage>
<lpage>1913</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.178.3.1904</pub-id>
<pub-id pub-id-type="pmid">17237441</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-19-01212">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padilla</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Phipps</surname>
<given-names>R.P.</given-names>
</name>
</person-group>
<article-title>Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists</article-title>
<source/>Clin. Immunol.
          <year>2002</year>
<volume>103</volume>
<fpage>22</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1006/clim.2001.5181</pub-id>
<pub-id pub-id-type="pmid">11987982</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-19-01212">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paintlia</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Paintlia</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Stanislaus</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gilg</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin</article-title>
<source/>J. Neurosci. Res.
          <year>2004</year>
<volume>77</volume>
<fpage>63</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.20130</pub-id>
<pub-id pub-id-type="pmid">15197739</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-19-01212">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klopfleisch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Merkler</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Klöppner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schedensack</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jeserich</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Althaus</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Brück</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo</article-title>
<source/>J. Neurosci.
          <year>2008</year>
<volume>28</volume>
<fpage>13609</fpage>
<lpage>13614</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2765-08.2008</pub-id>
<pub-id pub-id-type="pmid">19074034</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-19-01212">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miron</surname>
<given-names>V.E.</given-names>
</name>
<name>
<surname>Zehntner</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Kuhlmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ludwin</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Bedell</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Antel</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Statin therapy inhibits remyelination in the central nervous system</article-title>
<source/>Am. J. Pathol.
          <year>2009</year>
<volume>174</volume>
<fpage>1880</fpage>
<lpage>1890</lpage>
<pub-id pub-id-type="doi">10.2353/ajpath.2009.080947</pub-id>
<pub-id pub-id-type="pmid">19349355</pub-id>
</element-citation>
</ref>
<ref id="B137-ijms-19-01212">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fancy</surname>
<given-names>S.P.J.</given-names>
</name>
<name>
<surname>Baranzini</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yuk</surname>
<given-names>D.-I.</given-names>
</name>
<name>
<surname>Irvine</surname>
<given-names>K.-A.</given-names>
</name>
<name>
<surname>Kaing</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sanai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>R.J.M.</given-names>
</name>
<name>
<surname>Rowitch</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS</article-title>
<source/>Genes Dev.
          <year>2009</year>
<volume>23</volume>
<fpage>1571</fpage>
<lpage>1585</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1806309</pub-id>
<pub-id pub-id-type="pmid">19515974</pub-id>
</element-citation>
</ref>
<ref id="B138-ijms-19-01212">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiguchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kishioka</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Chemokines and cytokines in neuroinflammation leading to neuropathic pain</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2012</year>
<volume>12</volume>
<fpage>55</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2011.10.007</pub-id>
<pub-id pub-id-type="pmid">22019566</pub-id>
</element-citation>
</ref>
<ref id="B139-ijms-19-01212">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kam</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Quaranta</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Cadherin-bound beta-catenin feeds into the Wnt pathway upon adherens junctions dissociation: Evidence for an intersection between beta-catenin pools</article-title>
<source/>PLoS ONE
          <year>2009</year>
<volume>4</volume>
<elocation-id>e4580</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004580</pub-id>
<pub-id pub-id-type="pmid">19238201</pub-id>
</element-citation>
</ref>
<ref id="B140-ijms-19-01212">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lock</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hermans</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pedotti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brendolan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schadt</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Garren</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Langer-Gould</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Strober</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cannella</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Allard</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis</article-title>
<source/>Nat. Med.
          <year>2002</year>
<volume>8</volume>
<fpage>500</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.1038/nm0502-500</pub-id>
<pub-id pub-id-type="pmid">11984595</pub-id>
</element-citation>
</ref>
<ref id="B141-ijms-19-01212">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padden</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leech</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kirk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brankin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>McQuaid</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Differences in expression of junctional adhesion molecule-A and beta-catenin in multiple sclerosis brain tissue: Increasing evidence for the role of tight junction pathology</article-title>
<source/>Acta Neuropathol.
          <year>2007</year>
<volume>113</volume>
<fpage>177</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-006-0145-x</pub-id>
<pub-id pub-id-type="pmid">17024496</pub-id>
</element-citation>
</ref>
<ref id="B142-ijms-19-01212">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacoppo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Soundara Rajan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>De Nicola</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Iori</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mazzon</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Moringin activates Wnt canonical pathway by inhibiting GSK3β in a mouse model of experimental autoimmune encephalomyelitis</article-title>
<source/>Drug Des. Dev. Ther.
          <year>2016</year>
<volume>10</volume>
<fpage>3291</fpage>
<lpage>3304</lpage>
<pub-id pub-id-type="doi">10.2147/DDDT.S110514</pub-id>
<pub-id pub-id-type="pmid">27784989</pub-id>
</element-citation>
</ref>
<ref id="B143-ijms-19-01212">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galuppo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giacoppo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Nicola</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Iori</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Navarra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mazzon</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Antiinflammatory activity of glucomoringin isothiocyanate in a mouse model of experimental autoimmune encephalomyelitis</article-title>
<source/>Fitoterapia
          <year>2014</year>
<volume>95</volume>
<fpage>160</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/j.fitote.2014.03.018</pub-id>
<pub-id pub-id-type="pmid">24685508</pub-id>
</element-citation>
</ref>
<ref id="B144-ijms-19-01212">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacoppo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Galuppo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montaut</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iori</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rollin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mazzon</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases</article-title>
<source/>Fitoterapia
          <year>2015</year>
<volume>106</volume>
<fpage>12</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.fitote.2015.08.001</pub-id>
<pub-id pub-id-type="pmid">26254971</pub-id>
</element-citation>
</ref>
<ref id="B145-ijms-19-01212">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pate</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Stringari</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sprowl-Tanio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>TeSlaa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hoverter</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>McQuade</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Digman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Teitell</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer</article-title>
<source/>EMBO J.
          <year>2014</year>
<volume>33</volume>
<fpage>1454</fpage>
<lpage>1473</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201488598</pub-id>
<pub-id pub-id-type="pmid">24825347</pub-id>
</element-citation>
</ref>
<ref id="B146-ijms-19-01212">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallée</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vallée</surname>
<given-names>J.-N.</given-names>
</name>
</person-group>
<article-title>Warburg effect hypothesis in autism Spectrum disorders</article-title>
<source/>Mol. Brain
          <year>2018</year>
<volume>11</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/s13041-017-0343-6</pub-id>
<pub-id pub-id-type="pmid">29301575</pub-id>
</element-citation>
</ref>
<ref id="B147-ijms-19-01212">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Chaturvedi</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>B.B.</given-names>
</name>
</person-group>
<article-title>Oxidative stress, inflammation, and cancer: How are they linked?</article-title>
<source/>Free Radic. Biol. Med.
          <year>2010</year>
<volume>49</volume>
<fpage>1603</fpage>
<lpage>1616</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.09.006</pub-id>
<pub-id pub-id-type="pmid">20840865</pub-id>
</element-citation>
</ref>
<ref id="B148-ijms-19-01212">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.-K.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>Y.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway</article-title>
<source/>Exp. Cell Res.
          <year>2004</year>
<volume>297</volume>
<fpage>424</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2004.03.034</pub-id>
<pub-id pub-id-type="pmid">15212945</pub-id>
</element-citation>
</ref>
<ref id="B149-ijms-19-01212">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells</article-title>
<source/>Brain Res.
          <year>2010</year>
<volume>1366</volume>
<fpage>27</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.10.032</pub-id>
<pub-id pub-id-type="pmid">20969832</pub-id>
</element-citation>
</ref>
<ref id="B150-ijms-19-01212">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zha</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2011</year>
<volume>108</volume>
<fpage>4129</fpage>
<lpage>4134</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1014769108</pub-id>
<pub-id pub-id-type="pmid">21325052</pub-id>
</element-citation>
</ref>
<ref id="B151-ijms-19-01212">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname>
<given-names>G.L.</given-names>
</name>
</person-group>
<article-title>HIF-1: Upstream and downstream of cancer metabolism</article-title>
<source/>Curr. Opin. Genet. Dev.
          <year>2010</year>
<volume>20</volume>
<fpage>51</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2009.10.009</pub-id>
<pub-id pub-id-type="pmid">19942427</pub-id>
</element-citation>
</ref>
<ref id="B152-ijms-19-01212">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldbeter</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Patterns of spatiotemporal organization in an allosteric enzyme model</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1973</year>
<volume>70</volume>
<fpage>3255</fpage>
<lpage>3259</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.70.11.3255</pub-id>
<pub-id pub-id-type="pmid">4274133</pub-id>
</element-citation>
</ref>
<ref id="B153-ijms-19-01212">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cambron</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D’Haeseleer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Laureys</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Clinckers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Debruyne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>De Keyser</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis</article-title>
<source/>J. Cereb. Blood Flow Metab.
          <year>2012</year>
<volume>32</volume>
<fpage>413</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2011.193</pub-id>
<pub-id pub-id-type="pmid">22214904</pub-id>
</element-citation>
</ref>
<ref id="B154-ijms-19-01212">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hattingen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Magerkurth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pilatus</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hübers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wahl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ziemann</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis</article-title>
<source/>NMR Biomed.
          <year>2011</year>
<volume>24</volume>
<fpage>536</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="doi">10.1002/nbm.1621</pub-id>
<pub-id pub-id-type="pmid">21674655</pub-id>
</element-citation>
</ref>
<ref id="B155-ijms-19-01212">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trapp</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Stys</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis</article-title>
<source/>Lancet Neurol.
          <year>2009</year>
<volume>8</volume>
<fpage>280</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(09)70043-2</pub-id>
<pub-id pub-id-type="pmid">19233038</pub-id>
</element-citation>
</ref>
<ref id="B156-ijms-19-01212">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Ziabreva</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lassmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Mahad</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis</article-title>
<source/>Ann. Neurol.
          <year>2011</year>
<volume>69</volume>
<fpage>481</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="doi">10.1002/ana.22109</pub-id>
<pub-id pub-id-type="pmid">21446022</pub-id>
</element-citation>
</ref>
<ref id="B157-ijms-19-01212">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witte</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Bø</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rodenburg</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Belien</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Musters</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hazes</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wintjes</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Smeitink</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Geurts</surname>
<given-names>J.J.G.</given-names>
</name>
<name>
<surname>De Vries</surname>
<given-names>H.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enhanced number and activity of mitochondria in multiple sclerosis lesions</article-title>
<source/>J. Pathol.
          <year>2009</year>
<volume>219</volume>
<fpage>193</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1002/path.2582</pub-id>
<pub-id pub-id-type="pmid">19591199</pub-id>
</element-citation>
</ref>
<ref id="B158-ijms-19-01212">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gebregiworgis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Massilamany</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gangaplara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Illes</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Powers</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica</article-title>
<source/>J. Proteome Res.
          <year>2016</year>
<volume>15</volume>
<fpage>659</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jproteome.5b01111</pub-id>
<pub-id pub-id-type="pmid">26759122</pub-id>
</element-citation>
</ref>
<ref id="B159-ijms-19-01212">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nijland</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Molenaar</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>van der Pol</surname>
<given-names>S.M.A.</given-names>
</name>
<name>
<surname>van der Valk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>van Noorden</surname>
<given-names>C.J.F.</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>van Horssen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2015</year>
<volume>3</volume>
<fpage>79</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-015-0261-8</pub-id>
<pub-id pub-id-type="pmid">26637184</pub-id>
</element-citation>
</ref>
<ref id="B160-ijms-19-01212">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Riccardis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rizzello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferramosca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Urso</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>De Robertis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Danieli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giudetti</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Trianni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zara</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Maffia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Bioenergetics profile of CD4(+) T cells in relapsing remitting multiple sclerosis subjects</article-title>
<source/>J. Biotechnol.
          <year>2015</year>
<volume>202</volume>
<fpage>31</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1016/j.jbiotec.2015.02.015</pub-id>
<pub-id pub-id-type="pmid">25701681</pub-id>
</element-citation>
</ref>
<ref id="B161-ijms-19-01212">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kebir</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kreymborg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ifergan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dodelet-Devillers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cayrol</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giuliani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Arbour</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prat</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation</article-title>
<source/>Nat. Med.
          <year>2007</year>
<volume>13</volume>
<fpage>1173</fpage>
<lpage>1175</lpage>
<pub-id pub-id-type="doi">10.1038/nm1651</pub-id>
<pub-id pub-id-type="pmid">17828272</pub-id>
</element-citation>
</ref>
<ref id="B162-ijms-19-01212">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Riccardis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ferramosca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Danieli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trianni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zara</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>De Robertis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maffia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Metabolic response to glatiramer acetate therapy in multiple sclerosis patients</article-title>
<source/>BBA Clin.
          <year>2016</year>
<volume>6</volume>
<fpage>131</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbacli.2016.10.004</pub-id>
<pub-id pub-id-type="pmid">27785417</pub-id>
</element-citation>
</ref>
<ref id="B163-ijms-19-01212">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauernfeind</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Barks</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Duka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Sherwood</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Aerobic glycolysis in the primate brain: Reconsidering the implications for growth and maintenance</article-title>
<source/>Brain Struct. Funct.
          <year>2014</year>
<volume>219</volume>
<fpage>1149</fpage>
<lpage>1167</lpage>
<pub-id pub-id-type="doi">10.1007/s00429-013-0662-z</pub-id>
<pub-id pub-id-type="pmid">24185460</pub-id>
</element-citation>
</ref>
<ref id="B164-ijms-19-01212">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bongarzone</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Pasquini</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>E.F.</given-names>
</name>
</person-group>
<article-title>Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species</article-title>
<source/>J. Neurosci. Res.
          <year>1995</year>
<volume>41</volume>
<fpage>213</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.490410209</pub-id>
<pub-id pub-id-type="pmid">7650757</pub-id>
</element-citation>
</ref>
<ref id="B165-ijms-19-01212">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brand</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Hermfisse</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species</article-title>
<source/>FASEB J.
          <year>1997</year>
<volume>11</volume>
<fpage>388</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1096/fasebj.11.5.9141507</pub-id>
<pub-id pub-id-type="pmid">9141507</pub-id>
</element-citation>
</ref>
<ref id="B166-ijms-19-01212">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Rodriguez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bolaños</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration</article-title>
<source/>Cell Death Differ.
          <year>2012</year>
<volume>19</volume>
<fpage>1582</fpage>
<lpage>1589</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2012.33</pub-id>
<pub-id pub-id-type="pmid">22421967</pub-id>
</element-citation>
</ref>
<ref id="B167-ijms-19-01212">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>E.-A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High glucose-induced expression of inflammatory cytokines and reactive oxygen species in cultured astrocytes</article-title>
<source/>Neuroscience
          <year>2012</year>
<volume>202</volume>
<fpage>58</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.11.062</pub-id>
<pub-id pub-id-type="pmid">22178606</pub-id>
</element-citation>
</ref>
<ref id="B168-ijms-19-01212">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Subramony</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Shuster</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stacpoole</surname>
<given-names>P.W.</given-names>
</name>
</person-group>
<article-title>The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients</article-title>
<source/>Mol. Genet. Metab.
          <year>2012</year>
<volume>106</volume>
<fpage>385</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2012.03.017</pub-id>
<pub-id pub-id-type="pmid">22896851</pub-id>
</element-citation>
</ref>
<ref id="B169-ijms-19-01212">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trofimova</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Araújo</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Strokina</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Fernie</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Bettendorff</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bunik</surname>
<given-names>V.I.</given-names>
</name>
</person-group>
<article-title>Consequences of the α-ketoglutarate dehydrogenase inhibition for neuronal metabolism and survival: Implications for neurodegenerative diseases</article-title>
<source/>Curr. Med. Chem.
          <year>2012</year>
<volume>19</volume>
<fpage>5895</fpage>
<lpage>5906</lpage>
<pub-id pub-id-type="doi">10.2174/092986712804143367</pub-id>
<pub-id pub-id-type="pmid">23061627</pub-id>
</element-citation>
</ref>
<ref id="B170-ijms-19-01212">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiepers</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Van Hecke</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vandenberghe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Van Oostende</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Demaerel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bormans</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Carton</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis</article-title>
<source/>Mult. Scler. J.
          <year>1997</year>
<volume>3</volume>
<fpage>8</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1177/135245859700300102</pub-id>
<pub-id pub-id-type="pmid">9160342</pub-id>
</element-citation>
</ref>
<ref id="B171-ijms-19-01212">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simone</surname>
<given-names>I.L.</given-names>
</name>
<name>
<surname>Tortorella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Federico</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liguori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lucivero</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Giannini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carrara</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bellacosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Livrea</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Axonal damage in multiple sclerosis plaques: A combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study</article-title>
<source/>J. Neurol. Sci.
          <year>2001</year>
<volume>182</volume>
<fpage>143</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-510X(00)00464-0</pub-id>
<pub-id pub-id-type="pmid">11137520</pub-id>
</element-citation>
</ref>
<ref id="B172-ijms-19-01212">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amorini</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Nociti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Petzold</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gasperini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Quartuccio</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lazzarino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Pietro</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Belli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Signoretti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vagnozzi</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum lactate as a novel potential biomarker in multiple sclerosis</article-title>
<source/>Biochim. Biophys. Acta
          <year>2014</year>
<volume>1842</volume>
<fpage>1137</fpage>
<lpage>1143</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2014.04.005</pub-id>
<pub-id pub-id-type="pmid">24726946</pub-id>
</element-citation>
</ref>
<ref id="B173-ijms-19-01212">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petzold</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nijland</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Balk</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Amorini</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Lazzarino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wattjes</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Gasperini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>van der Valk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tavazzi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lazzarino</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Visual pathway neurodegeneration winged by mitochondrial dysfunction</article-title>
<source/>Ann. Clin. Transl. Neurol.
          <year>2015</year>
<volume>2</volume>
<fpage>140</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.157</pub-id>
<pub-id pub-id-type="pmid">25750919</pub-id>
</element-citation>
</ref>
<ref id="B174-ijms-19-01212">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schocke</surname>
<given-names>M.F.H.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Felber</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Deisenhammer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kremser</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Seppi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aichner</surname>
<given-names>F.T.</given-names>
</name>
</person-group>
<article-title>Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy</article-title>
<source/>NeuroImage
          <year>2003</year>
<volume>20</volume>
<fpage>1253</fpage>
<lpage>1263</lpage>
<pub-id pub-id-type="doi">10.1016/S1053-8119(03)00409-9</pub-id>
<pub-id pub-id-type="pmid">14568494</pub-id>
</element-citation>
</ref>
<ref id="B175-ijms-19-01212">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lutz</surname>
<given-names>N.W.</given-names>
</name>
<name>
<surname>Viola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Malikova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Confort-Gouny</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Audoin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ranjeva</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cozzone</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid</article-title>
<source/>PLoS ONE
          <year>2007</year>
<volume>2</volume>
<elocation-id>e595</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0000595</pub-id>
<pub-id pub-id-type="pmid">17611627</pub-id>
</element-citation>
</ref>
<ref id="B176-ijms-19-01212">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Regenold</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Phatak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Makley</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Kling</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression</article-title>
<source/>J. Neurol. Sci.
          <year>2008</year>
<volume>275</volume>
<fpage>106</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2008.07.032</pub-id>
<pub-id pub-id-type="pmid">18783801</pub-id>
</element-citation>
</ref>
<ref id="B177-ijms-19-01212">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simone</surname>
<given-names>I.L.</given-names>
</name>
<name>
<surname>Federico</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Trojano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tortorella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liguori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giannini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Picciola</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Natile</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Livrea</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques</article-title>
<source/>J. Neurol. Sci.
          <year>1996</year>
<volume>144</volume>
<fpage>182</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-510X(96)00224-9</pub-id>
<pub-id pub-id-type="pmid">8994122</pub-id>
</element-citation>
</ref>
<ref id="B178-ijms-19-01212">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hogenesch</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y.Z.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bradfield</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1998</year>
<volume>95</volume>
<fpage>5474</fpage>
<lpage>5479</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.10.5474</pub-id>
<pub-id pub-id-type="pmid">9576906</pub-id>
</element-citation>
</ref>
<ref id="B179-ijms-19-01212">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gekakis</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Staknis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Wilsbacher</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Role of the CLOCK protein in the mammalian circadian mechanism</article-title>
<source/>Science
          <year>1998</year>
<volume>280</volume>
<fpage>1564</fpage>
<lpage>1569</lpage>
<pub-id pub-id-type="doi">10.1126/science.280.5369.1564</pub-id>
<pub-id pub-id-type="pmid">9616112</pub-id>
</element-citation>
</ref>
<ref id="B180-ijms-19-01212">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reppert</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Coordination of circadian timing in mammals</article-title>
<source/>Nature
          <year>2002</year>
<volume>418</volume>
<fpage>935</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="doi">10.1038/nature00965</pub-id>
<pub-id pub-id-type="pmid">12198538</pub-id>
</element-citation>
</ref>
<ref id="B181-ijms-19-01212">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schibler</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Sassone-Corsi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>A web of circadian pacemakers</article-title>
<source/>Cell
          <year>2002</year>
<volume>111</volume>
<fpage>919</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(02)01225-4</pub-id>
<pub-id pub-id-type="pmid">12507418</pub-id>
</element-citation>
</ref>
<ref id="B182-ijms-19-01212">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Molecular components of the mammalian circadian clock</article-title>
<source/>Hum. Mol. Genet.
          <year>2006</year>
<volume>15</volume>
<fpage>R271</fpage>
<lpage>R277</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddl207</pub-id>
<pub-id pub-id-type="pmid">16987893</pub-id>
</element-citation>
</ref>
<ref id="B183-ijms-19-01212">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Somma</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>K.W.C.</given-names>
</name>
<name>
<surname>Tresidder</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Ghasemlou</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Chronobiological regulation of psychosocial and physiological outcomes in multiple sclerosis</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.03.011</pub-id>
<pub-id pub-id-type="pmid">29548931</pub-id>
</element-citation>
</ref>
<ref id="B184-ijms-19-01212">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedström</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Åkerstedt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hillert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Alfredsson</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Shift work at young age is associated with increased risk for multiple sclerosis</article-title>
<source/>Ann. Neurol.
          <year>2011</year>
<volume>70</volume>
<fpage>733</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="doi">10.1002/ana.22597</pub-id>
<pub-id pub-id-type="pmid">22006815</pub-id>
</element-citation>
</ref>
<ref id="B185-ijms-19-01212">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedström</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Åkerstedt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Alfredsson</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Shift work influences multiple sclerosis risk</article-title>
<source/>Mult. Scler. J.
          <year>2015</year>
<volume>21</volume>
<fpage>1195</fpage>
<lpage>1199</lpage>
<pub-id pub-id-type="doi">10.1177/1352458514563592</pub-id>
<pub-id pub-id-type="pmid">25698167</pub-id>
</element-citation>
</ref>
<ref id="B186-ijms-19-01212">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haspel</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Chettimada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shaik</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Raby</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Cernadas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Process</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hunninghake</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Ifedigbo</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Circadian rhythm reprogramming during lung inflammation</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<fpage>4753</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms5753</pub-id>
<pub-id pub-id-type="pmid">25208554</pub-id>
</element-citation>
</ref>
<ref id="B187-ijms-19-01212">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hsuchou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kastin</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Sleep restriction impairs blood-brain barrier function</article-title>
<source/>J. Neurosci.
          <year>2014</year>
<volume>34</volume>
<fpage>14697</fpage>
<lpage>14706</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2111-14.2014</pub-id>
<pub-id pub-id-type="pmid">25355222</pub-id>
</element-citation>
</ref>
<ref id="B188-ijms-19-01212">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akpinar</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tokgöz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gökbel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Okudan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Uğuz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis</article-title>
<source/>Psychiatry Res.
          <year>2008</year>
<volume>161</volume>
<fpage>253</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2007.11.022</pub-id>
<pub-id pub-id-type="pmid">18848732</pub-id>
</element-citation>
</ref>
<ref id="B189-ijms-19-01212">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marck</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Neate</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Weiland</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Jelinek</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Prevalence of Comorbidities, Overweight and Obesity in an International Sample of People with Multiple Sclerosis and Associations with Modifiable Lifestyle Factors</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0148573</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0148573</pub-id>
<pub-id pub-id-type="pmid">26849357</pub-id>
</element-citation>
</ref>
<ref id="B190-ijms-19-01212">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lunde</surname>
<given-names>H.M.B.</given-names>
</name>
<name>
<surname>Bjorvatn</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Myhr</surname>
<given-names>K.-M.</given-names>
</name>
<name>
<surname>Bø</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Clinical assessment and management of sleep disorders in multiple sclerosis: A literature review</article-title>
<source/>Acta Neurol. Scand.
          <year>2013</year>
<volume>127</volume>
<fpage>24</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12046</pub-id>
<pub-id pub-id-type="pmid">23190288</pub-id>
</element-citation>
</ref>
<ref id="B191-ijms-19-01212">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turek</surname>
<given-names>F.W.</given-names>
</name>
<name>
<surname>Dugovic</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zee</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Current understanding of the circadian clock and the clinical implications for neurological disorders</article-title>
<source/>Arch. Neurol.
          <year>2001</year>
<volume>58</volume>
<fpage>1781</fpage>
<lpage>1787</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.58.11.1781</pub-id>
<pub-id pub-id-type="pmid">11708984</pub-id>
</element-citation>
</ref>
<ref id="B192-ijms-19-01212">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Attarian</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Duntley</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>The relationship of sleep disturbances and fatigue in multiple sclerosis</article-title>
<source/>Arch. Neurol.
          <year>2004</year>
<volume>61</volume>
<fpage>525</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.61.4.525</pub-id>
<pub-id pub-id-type="pmid">15096400</pub-id>
</element-citation>
</ref>
<ref id="B193-ijms-19-01212">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najafi</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Toghianifar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Etemadifar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haghighi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maghzi</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Akbari</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Circadian rhythm sleep disorders in patients with multiple sclerosis and its association with fatigue: A case-control study</article-title>
<source/>J. Res. Med. Sci.
          <year>2013</year>
<volume>18</volume>
<fpage>S71</fpage>
<lpage>S73</lpage>
<pub-id pub-id-type="pmid">23961292</pub-id>
</element-citation>
</ref>
<ref id="B194-ijms-19-01212">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayache</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Chalah</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Fatigue in multiple sclerosis—Insights into evaluation and management</article-title>
<source/>Neurophysiol. Clin. Clin. Neurophysiol.
          <year>2017</year>
<volume>47</volume>
<fpage>139</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1016/j.neucli.2017.02.004</pub-id>
<pub-id pub-id-type="pmid">28416274</pub-id>
</element-citation>
</ref>
<ref id="B195-ijms-19-01212">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsujino</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Role of orexin in modulating arousal, feeding, and motivation</article-title>
<source/>Front. Behav. Neurosci.
          <year>2013</year>
<volume>7</volume>
<fpage>28</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2013.00028</pub-id>
<pub-id pub-id-type="pmid">23616752</pub-id>
</element-citation>
</ref>
<ref id="B196-ijms-19-01212">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyashchenko</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Mileykovskiy</surname>
<given-names>B.Y.</given-names>
</name>
<name>
<surname>Maidment</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.-F.</given-names>
</name>
<name>
<surname>John</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peever</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Release of hypocretin (orexin) during waking and sleep states</article-title>
<source/>J. Neurosci.
          <year>2002</year>
<volume>22</volume>
<fpage>5282</fpage>
<lpage>5286</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-13-05282.2002</pub-id>
<pub-id pub-id-type="pmid">12097478</pub-id>
</element-citation>
</ref>
<ref id="B197-ijms-19-01212">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kanbayashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mezaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iseki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsubayashi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Matsui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shibasaki</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis</article-title>
<source/>J. Neurol.
          <year>2004</year>
<volume>251</volume>
<fpage>885</fpage>
<lpage>886</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-004-0442-z</pub-id>
<pub-id pub-id-type="pmid">15258796</pub-id>
</element-citation>
</ref>
<ref id="B198-ijms-19-01212">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grossberg</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Leinninger</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Levasseur</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Inflammation-induced lethargy is mediated by suppression of orexin neuron activity</article-title>
<source/>J. Neurosci.
          <year>2011</year>
<volume>31</volume>
<fpage>11376</fpage>
<lpage>11386</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2311-11.2011</pub-id>
<pub-id pub-id-type="pmid">21813697</pub-id>
</element-citation>
</ref>
<ref id="B199-ijms-19-01212">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pokryszko-Dragan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frydecka</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kosmaczewska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ciszak</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bilińska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gruszka</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Podemski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Frydecka</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis</article-title>
<source/>Clin. Neurol. Neurosurg.
          <year>2012</year>
<volume>114</volume>
<fpage>1153</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="doi">10.1016/j.clineuro.2012.02.048</pub-id>
<pub-id pub-id-type="pmid">22425464</pub-id>
</element-citation>
</ref>
<ref id="B200-ijms-19-01212">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boddum</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Jennum</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Kornum</surname>
<given-names>B.R.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Level Fluctuates with Season and Correlates with Day Length</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0151288</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0151288</pub-id>
<pub-id pub-id-type="pmid">27008404</pub-id>
</element-citation>
</ref>
<ref id="B201-ijms-19-01212">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taphoorn</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>van Someren</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Snoek</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Strijers</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Visscher</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Waal</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Polman</surname>
<given-names>C.H.</given-names>
</name>
</person-group>
<article-title>Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis</article-title>
<source/>J. Neurol.
          <year>1993</year>
<volume>240</volume>
<fpage>446</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1007/BF00867360</pub-id>
<pub-id pub-id-type="pmid">8410088</pub-id>
</element-citation>
</ref>
<ref id="B202-ijms-19-01212">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farez</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Mascanfroni</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Méndez-Huergo</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Yeste</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Murugaiyan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Garo</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Balbuena Aguirre</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ysrraelit</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses</article-title>
<source/>Cell
          <year>2015</year>
<volume>162</volume>
<fpage>1338</fpage>
<lpage>1352</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.08.025</pub-id>
<pub-id pub-id-type="pmid">26359987</pub-id>
</element-citation>
</ref>
<ref id="B203-ijms-19-01212">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torkildsen</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Aarseth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Benjaminsen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Celius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Holmøy</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kampman</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Løken-Amsrud</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Midgard</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Myhr</surname>
<given-names>K.-M.</given-names>
</name>
<name>
<surname>Riise</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Month of birth and risk of multiple sclerosis: Confounding and adjustments</article-title>
<source/>Ann. Clin. Transl. Neurol.
          <year>2014</year>
<volume>1</volume>
<fpage>141</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.37</pub-id>
<pub-id pub-id-type="pmid">25356394</pub-id>
</element-citation>
</ref>
<ref id="B204-ijms-19-01212">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynolds</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Krementsov</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Raza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bartiss</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Teuscher</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Modeling month-season of birth as a risk factor in mouse models of chronic disease: From multiple sclerosis to autoimmune encephalomyelitis</article-title>
<source/>FASEB J.
          <year>2017</year>
<volume>31</volume>
<fpage>2709</fpage>
<lpage>2719</lpage>
<pub-id pub-id-type="doi">10.1096/fj.201700062</pub-id>
<pub-id pub-id-type="pmid">28292961</pub-id>
</element-citation>
</ref>
<ref id="B205-ijms-19-01212">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dang</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Tesfagiorgis</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Kerfoot</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Meningeal Infiltration of the Spinal Cord by Non-Classically Activated B Cells is Associated with Chronic Disease Course in a Spontaneous B Cell-Dependent Model of CNS Autoimmune Disease</article-title>
<source/>Front. Immunol.
          <year>2015</year>
<volume>6</volume>
<fpage>470</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2015.00470</pub-id>
<pub-id pub-id-type="pmid">26441975</pub-id>
</element-citation>
</ref>
<ref id="B206-ijms-19-01212">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Rollins</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ruhn</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Stubblefield</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Kashiwada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>L.V.</given-names>
</name>
</person-group>
<article-title>TH17 cell differentiation is regulated by the circadian clock</article-title>
<source/>Science
          <year>2013</year>
<volume>342</volume>
<fpage>727</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="doi">10.1126/science.1243884</pub-id>
<pub-id pub-id-type="pmid">24202171</pub-id>
</element-citation>
</ref>
<ref id="B207-ijms-19-01212">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T.L.</given-names>
</name>
</person-group>
<article-title>Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment</article-title>
<source/>Bone
          <year>2004</year>
<volume>35</volume>
<fpage>83</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/j.bone.2004.03.019</pub-id>
<pub-id pub-id-type="pmid">15207744</pub-id>
</element-citation>
</ref>
<ref id="B208-ijms-19-01212">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soták</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sumová</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pácha</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Cross-talk between the circadian clock and the cell cycle in cancer</article-title>
<source/>Ann. Med.
          <year>2014</year>
<volume>46</volume>
<fpage>221</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.3109/07853890.2014.892296</pub-id>
<pub-id pub-id-type="pmid">24779962</pub-id>
</element-citation>
</ref>
<ref id="B209-ijms-19-01212">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010</article-title>
<source/>J. Am. Coll. Cardiol.
          <year>2012</year>
<volume>60</volume>
<fpage>599</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2012.04.026</pub-id>
<pub-id pub-id-type="pmid">22796254</pub-id>
</element-citation>
</ref>
<ref id="B210-ijms-19-01212">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasuniwa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.-Y.</given-names>
</name>
<name>
<surname>Shimajiri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sasaguri</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kashiwagi</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e15330</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0015330</pub-id>
<pub-id pub-id-type="pmid">21203463</pub-id>
</element-citation>
</ref>
<ref id="B211-ijms-19-01212">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janich</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pascual</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Merlos-Suárez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Batlle</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ripperger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.-Y.M.</given-names>
</name>
<name>
<surname>Obrietan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Di Croce</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benitah</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>The circadian molecular clock creates epidermal stem cell heterogeneity</article-title>
<source/>Nature
          <year>2011</year>
<volume>480</volume>
<fpage>209</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1038/nature10649</pub-id>
<pub-id pub-id-type="pmid">22080954</pub-id>
</element-citation>
</ref>
<ref id="B212-ijms-19-01212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavtar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rudolf</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Maver</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hodžić</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Starčević Čizmarević</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Živković</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Šega Jazbec</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Klemenc Ketiš</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kapović</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dinčić</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis</article-title>
<source/>PLoS ONE
          <year>2018</year>
<volume>13</volume>
<elocation-id>e0190601</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0190601</pub-id>
<pub-id pub-id-type="pmid">29324865</pub-id>
</element-citation>
</ref>
<ref id="B213-ijms-19-01212">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Over-expression of circadian clock gene Bmal1 affects proliferation and the canonical Wnt pathway in NIH-3T3 cells</article-title>
<source/>Cell Biochem. Funct.
          <year>2013</year>
<volume>31</volume>
<fpage>166</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1002/cbf.2871</pub-id>
<pub-id pub-id-type="pmid">22961668</pub-id>
</element-citation>
</ref>
<ref id="B214-ijms-19-01212">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sassone-Corsi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Metabolism and cancer: The circadian clock connection</article-title>
<source/>Nat. Rev. Cancer
          <year>2009</year>
<volume>9</volume>
<fpage>886</fpage>
<lpage>896</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2747</pub-id>
<pub-id pub-id-type="pmid">19935677</pub-id>
</element-citation>
</ref>
<ref id="B215-ijms-19-01212">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Ansell</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Ohmori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>E.-Y.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Peña</surname>
<given-names>M.M.O.</given-names>
</name>
<name>
<surname>Hrushesky</surname>
<given-names>W.J.M.</given-names>
</name>
</person-group>
<article-title>Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice</article-title>
<source/>J. Biochem.
          <year>2009</year>
<volume>145</volume>
<fpage>289</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1093/jb/mvn167</pub-id>
<pub-id pub-id-type="pmid">19106159</pub-id>
</element-citation>
</ref>
<ref id="B216-ijms-19-01212">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffield</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Best</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Meurers</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Bittner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Loros</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Dunlap</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells</article-title>
<source/>Curr. Biol.
          <year>2002</year>
<volume>12</volume>
<fpage>551</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1016/S0960-9822(02)00765-0</pub-id>
<pub-id pub-id-type="pmid">11937023</pub-id>
</element-citation>
</ref>
<ref id="B217-ijms-19-01212">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sancar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lindsey-Boltz</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Unsal-Kaçmaz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Linn</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints</article-title>
<source/>Annu. Rev. Biochem.
          <year>2004</year>
<volume>73</volume>
<fpage>39</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.biochem.73.011303.073723</pub-id>
<pub-id pub-id-type="pmid">15189136</pub-id>
</element-citation>
</ref>
<ref id="B218-ijms-19-01212">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Bookout</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Straume</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mangelsdorf</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Nuclear receptor expression links the circadian clock to metabolism</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>801</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.06.050</pub-id>
<pub-id pub-id-type="pmid">16923398</pub-id>
</element-citation>
</ref>
<ref id="B219-ijms-19-01212">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Aoyagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Systemic PPARγ deletion impairs circadian rhythms of behavior and metabolism</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e38117</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0038117</pub-id>
<pub-id pub-id-type="pmid">22899986</pub-id>
</element-citation>
</ref>
<ref id="B220-ijms-19-01212">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.-X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.-D.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>W.-Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.-D.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.-Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.-D.</given-names>
</name>
</person-group>
<article-title>PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes</article-title>
<source/>J. Alzheimers Dis.
          <year>2010</year>
<volume>20</volume>
<fpage>1189</fpage>
<lpage>1199</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2010-091336</pub-id>
<pub-id pub-id-type="pmid">20413894</pub-id>
</element-citation>
</ref>
<ref id="B221-ijms-19-01212">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontaine</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Duguay</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Helledie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vu-Dac</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gervois</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Soncin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mandrup</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fruchart</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Fruchart-Najib</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation</article-title>
<source/>J. Biol. Chem.
          <year>2003</year>
<volume>278</volume>
<fpage>37672</fpage>
<lpage>37680</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M304664200</pub-id>
<pub-id pub-id-type="pmid">12821652</pub-id>
</element-citation>
</ref>
<ref id="B222-ijms-19-01212">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Douris</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Strayer</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Fogerty</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lourim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Besharse</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Loss of Nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis and diet-induced obesity</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>9888</fpage>
<lpage>9893</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0702448104</pub-id>
<pub-id pub-id-type="pmid">17517647</pub-id>
</element-citation>
</ref>
<ref id="B223-ijms-19-01212">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>PPARs Integrate the Mammalian Clock and Energy Metabolism</article-title>
<source/>PPAR Res.
          <year>2014</year>
<volume>2014</volume>
<fpage>653017</fpage>
<pub-id pub-id-type="doi">10.1155/2014/653017</pub-id>
<pub-id pub-id-type="pmid">24693278</pub-id>
</element-citation>
</ref>
<ref id="B224-ijms-19-01212">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivanov</surname>
<given-names>I.I.</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tadokoro</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Lepelley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lafaille</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Cua</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Littman</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>1121</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.07.035</pub-id>
<pub-id pub-id-type="pmid">16990136</pub-id>
</element-citation>
</ref>
<ref id="B225-ijms-19-01212">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Unutmaz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Littman</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat</article-title>
<source/>Nat. Immunol.
          <year>2008</year>
<volume>9</volume>
<fpage>641</fpage>
<lpage>649</lpage>
<pub-id pub-id-type="doi">10.1038/ni.1610</pub-id>
<pub-id pub-id-type="pmid">18454151</pub-id>
</element-citation>
</ref>
<ref id="B226-ijms-19-01212">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Bishop-Bailey</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Estrada-Hernandez</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hla</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Puddington</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Padula</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses</article-title>
<source/>J. Immunol.
          <year>2000</year>
<volume>164</volume>
<fpage>1364</fpage>
<lpage>1371</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.164.3.1364</pub-id>
<pub-id pub-id-type="pmid">10640751</pub-id>
</element-citation>
</ref>
<ref id="B227-ijms-19-01212">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling</article-title>
<source/>Mol. Neurobiol.
          <year>2016</year>
<volume>53</volume>
<fpage>5356</fpage>
<lpage>5366</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-015-9462-1</pub-id>
<pub-id pub-id-type="pmid">26440666</pub-id>
</element-citation>
</ref>
<ref id="B228-ijms-19-01212">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lochner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peduto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cherrier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Langa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Varona</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Riethmacher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Si-Tahar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Santo</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Eberl</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells</article-title>
<source/>J. Exp. Med.
          <year>2008</year>
<volume>205</volume>
<fpage>1381</fpage>
<lpage>1393</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20080034</pub-id>
<pub-id pub-id-type="pmid">18504307</pub-id>
</element-citation>
</ref>
<ref id="B229-ijms-19-01212">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cermakian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Golombek</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nakao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mazzoccoli</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Crosstalk between the circadian clock circuitry and the immune system</article-title>
<source/>Chronobiol. Int.
          <year>2013</year>
<volume>30</volume>
<fpage>870</fpage>
<lpage>888</lpage>
<pub-id pub-id-type="doi">10.3109/07420528.2013.782315</pub-id>
<pub-id pub-id-type="pmid">23697902</pub-id>
</element-citation>
</ref>
<ref id="B230-ijms-19-01212">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cutolo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sulli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pincus</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Circadian use of glucocorticoids in rheumatoid arthritis</article-title>
<source/>Neuroimmunomodulation
          <year>2015</year>
<volume>22</volume>
<fpage>33</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1159/000362733</pub-id>
<pub-id pub-id-type="pmid">25227591</pub-id>
</element-citation>
</ref>
<ref id="B231-ijms-19-01212">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kern</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schultheiss</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schrempf</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Reichmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ziemssen</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis</article-title>
<source/>Psychoneuroendocrinology
          <year>2011</year>
<volume>36</volume>
<fpage>1505</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2011.04.004</pub-id>
<pub-id pub-id-type="pmid">21621332</pub-id>
</element-citation>
</ref>
<ref id="B232-ijms-19-01212">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wipfler</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Heikkinen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Harrer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pilz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Golaszewski</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Reuss</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Oschmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Circadian rhythmicity of inflammatory serum parameters: A neglected issue in the search of biomarkers in multiple sclerosis</article-title>
<source/>J. Neurol.
          <year>2013</year>
<volume>260</volume>
<fpage>221</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-012-6622-3</pub-id>
<pub-id pub-id-type="pmid">22875099</pub-id>
</element-citation>
</ref>
<ref id="B233-ijms-19-01212">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Powell</surname>
<given-names>D.J.H.</given-names>
</name>
<name>
<surname>Moss-Morris</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liossi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schlotz</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis</article-title>
<source/>Psychoneuroendocrinology
          <year>2015</year>
<volume>56</volume>
<fpage>120</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.03.010</pub-id>
<pub-id pub-id-type="pmid">25817406</pub-id>
</element-citation>
</ref>
<ref id="B234-ijms-19-01212">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melief</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>van Eden</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Teunissen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hamann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Uitdehaag</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huitinga</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter</article-title>
<source/>Acta Neuropathol.
          <year>2013</year>
<volume>126</volume>
<fpage>237</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-013-1140-7</pub-id>
<pub-id pub-id-type="pmid">23812288</pub-id>
</element-citation>
</ref>
<ref id="B235-ijms-19-01212">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>MacPhee</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Antoni</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat</article-title>
<source/>Immunology
          <year>1990</year>
<volume>70</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">2354853</pub-id>
</element-citation>
</ref>
<ref id="B236-ijms-19-01212">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gold</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Raji</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huitinga</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wiedemann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Heesen</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis</article-title>
<source/>J. Neuroimmunol.
          <year>2005</year>
<volume>165</volume>
<fpage>186</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.04.014</pub-id>
<pub-id pub-id-type="pmid">15935481</pub-id>
</element-citation>
</ref>
<ref id="B237-ijms-19-01212">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heidbrink</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Häusler</surname>
<given-names>S.F.M.</given-names>
</name>
<name>
<surname>Buttmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ossadnik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Strik</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buck</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Verbraak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>van Meurs</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krockenberger</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: Implications for lesion pathogenesis</article-title>
<source/>Brain. Behav. Immun.
          <year>2010</year>
<volume>24</volume>
<fpage>975</fpage>
<lpage>984</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2010.04.003</pub-id>
<pub-id pub-id-type="pmid">20385225</pub-id>
</element-citation>
</ref>
<ref id="B238-ijms-19-01212">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Brandt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lühder</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Tischner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wiehr</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Weissert</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reichardt</surname>
<given-names>H.M.</given-names>
</name>
</person-group>
<article-title>Enhanced glucocorticoid receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune responses</article-title>
<source/>Am. J. Pathol.
          <year>2007</year>
<volume>170</volume>
<fpage>1041</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="doi">10.2353/ajpath.2007.060804</pub-id>
<pub-id pub-id-type="pmid">17322387</pub-id>
</element-citation>
</ref>
<ref id="B239-ijms-19-01212">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellavance</surname>
<given-names>M.-A.</given-names>
</name>
<name>
<surname>Rivest</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The HPA—Immune Axis and the Immunomodulatory Actions of Glucocorticoids in the Brain</article-title>
<source/>Front. Immunol.
          <year>2014</year>
<volume>5</volume>
<fpage>136</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00136</pub-id>
<pub-id pub-id-type="pmid">24744759</pub-id>
</element-citation>
</ref>
<ref id="B240-ijms-19-01212">
<label>240.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Winsen</surname>
<given-names>L.M.L.</given-names>
</name>
<name>
<surname>Muris</surname>
<given-names>D.F.R.</given-names>
</name>
<name>
<surname>Polman</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Dijkstra</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>van den Berg</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Uitdehaag</surname>
<given-names>B.M.J.</given-names>
</name>
</person-group>
<article-title>Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2005</year>
<volume>90</volume>
<fpage>734</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2004-0306</pub-id>
<pub-id pub-id-type="pmid">15546910</pub-id>
</element-citation>
</ref>
<ref id="B241-ijms-19-01212">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Glucocorticoid-mediated Period2 induction delays the phase of circadian rhythm</article-title>
<source/>Nucleic Acids Res.
          <year>2013</year>
<volume>41</volume>
<fpage>6161</fpage>
<lpage>6174</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt307</pub-id>
<pub-id pub-id-type="pmid">23620290</pub-id>
</element-citation>
</ref>
<ref id="B242-ijms-19-01212">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>So</surname>
<given-names>A.Y.-L.</given-names>
</name>
<name>
<surname>Bernal</surname>
<given-names>T.U.</given-names>
</name>
<name>
<surname>Pillsbury</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>Glucocorticoid regulation of the circadian clock modulates glucose homeostasis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>17582</fpage>
<lpage>17587</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0909733106</pub-id>
<pub-id pub-id-type="pmid">19805059</pub-id>
</element-citation>
</ref>
<ref id="B243-ijms-19-01212">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Seremwe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Olala</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bollag</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells</article-title>
<source/>Mol. Cell. Endocrinol.
          <year>2014</year>
<volume>394</volume>
<fpage>119</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/j.mce.2014.07.007</pub-id>
<pub-id pub-id-type="pmid">25038520</pub-id>
</element-citation>
</ref>
<ref id="B244-ijms-19-01212">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csernus</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mess</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Biorhythms and pineal gland</article-title>
<source/>Neuro Endocrinol. Lett.
          <year>2003</year>
<volume>24</volume>
<fpage>404</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="pmid">15073565</pub-id>
</element-citation>
</ref>
<ref id="B245-ijms-19-01212">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mauriz</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Collado</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Veneroso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>González-Gallego</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A review of the molecular aspects of melatonin’s anti-inflammatory actions: Recent insights and new perspectives</article-title>
<source/>J. Pineal Res.
          <year>2013</year>
<volume>54</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2012.01014.x</pub-id>
<pub-id pub-id-type="pmid">22725668</pub-id>
</element-citation>
</ref>
<ref id="B246-ijms-19-01212">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crowley</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Eastman</surname>
<given-names>C.I.</given-names>
</name>
</person-group>
<article-title>Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>225</volume>
<fpage>825</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-012-2869-8</pub-id>
<pub-id pub-id-type="pmid">23001190</pub-id>
</element-citation>
</ref>
<ref id="B247-ijms-19-01212">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farez</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Calandri</surname>
<given-names>I.L.</given-names>
</name>
<name>
<surname>Correale</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Quintana</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory effects of melatonin in multiple sclerosis</article-title>
<source/>BioEssays
          <year>2016</year>
<volume>38</volume>
<fpage>1016</fpage>
<lpage>1026</lpage>
<pub-id pub-id-type="doi">10.1002/bies.201600018</pub-id>
<pub-id pub-id-type="pmid">27561251</pub-id>
</element-citation>
</ref>
<ref id="B248-ijms-19-01212">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandyk</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Awerbuch</surname>
<given-names>G.I.</given-names>
</name>
</person-group>
<article-title>Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis</article-title>
<source/>Int. J. Neurosci.
          <year>1992</year>
<volume>67</volume>
<fpage>173</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.3109/00207459208994783</pub-id>
<pub-id pub-id-type="pmid">1305632</pub-id>
</element-citation>
</ref>
<ref id="B249-ijms-19-01212">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sirianni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cormier</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity</article-title>
<source/>J. Neurosci.
          <year>2011</year>
<volume>31</volume>
<fpage>14496</fpage>
<lpage>14507</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3059-11.2011</pub-id>
<pub-id pub-id-type="pmid">21994366</pub-id>
</element-citation>
</ref>
<ref id="B250-ijms-19-01212">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosales-Corral</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Acuña-Castroviejo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Coto-Montes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boga</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Manchester</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Fuentes-Broto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Korkmaz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>D.-X.</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: Pathological mechanisms and the beneficial role of melatonin</article-title>
<source/>J. Pineal Res.
          <year>2012</year>
<volume>52</volume>
<fpage>167</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2011.00937.x</pub-id>
<pub-id pub-id-type="pmid">22107053</pub-id>
</element-citation>
</ref>
<ref id="B251-ijms-19-01212">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>D.X.</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK</article-title>
<source/>J. Pineal Res.
          <year>2013</year>
<volume>54</volume>
<fpage>245</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12010</pub-id>
<pub-id pub-id-type="pmid">22998574</pub-id>
</element-citation>
</ref>
<ref id="B252-ijms-19-01212">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>González-Yanes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>The role of melatonin in the cells of the innate immunity: A review</article-title>
<source/>J. Pineal Res.
          <year>2013</year>
<volume>55</volume>
<fpage>103</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12075</pub-id>
<pub-id pub-id-type="pmid">23889107</pub-id>
</element-citation>
</ref>
<ref id="B253-ijms-19-01212">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Melatonin: A well-documented antioxidant with conditional pro-oxidant actions</article-title>
<source/>J. Pineal Res.
          <year>2014</year>
<volume>57</volume>
<fpage>131</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12162</pub-id>
<pub-id pub-id-type="pmid">25060102</pub-id>
</element-citation>
</ref>
<ref id="B254-ijms-19-01212">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.-R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.-F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>G.-J.</given-names>
</name>
<name>
<surname>Sytwu</surname>
<given-names>H.-K.</given-names>
</name>
</person-group>
<article-title>Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis</article-title>
<source/>Int. Immunopharmacol.
          <year>2016</year>
<volume>31</volume>
<fpage>169</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2015.12.020</pub-id>
<pub-id pub-id-type="pmid">26735612</pub-id>
</element-citation>
</ref>
<ref id="B255-ijms-19-01212">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markowska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bialecka</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ciechanowska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koter</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Laskowska</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Karkucinska-Wieckowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Skwarlo-Sonta</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Effect of immunization on nocturnal NAT activity in chicken pineal gland</article-title>
<source/>Neuro Endocrinol. Lett.
          <year>2000</year>
<volume>21</volume>
<fpage>367</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="pmid">11452231</pub-id>
</element-citation>
</ref>
<ref id="B256-ijms-19-01212">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>P.A.C.M.</given-names>
</name>
<name>
<surname>Cecon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Markus</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>Z.S.</given-names>
</name>
</person-group>
<article-title>Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: Basis for a “feedback” of the immune response on circadian timing</article-title>
<source/>J. Pineal Res.
          <year>2006</year>
<volume>41</volume>
<fpage>344</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2006.00373.x</pub-id>
<pub-id pub-id-type="pmid">17014691</pub-id>
</element-citation>
</ref>
<ref id="B257-ijms-19-01212">
<label>257.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Bochenek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Król</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Krawczyńska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Antushevich</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pawlina</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Romanowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tomaszewska-Zaremba</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Central Interleukin-1β Suppresses the Nocturnal Secretion of Melatonin</article-title>
<source/>Mediators Inflamm.
          <year>2016</year>
<volume>2016</volume>
<fpage>2589483</fpage>
<pub-id pub-id-type="doi">10.1155/2016/2589483</pub-id>
<pub-id pub-id-type="pmid">27212805</pub-id>
</element-citation>
</ref>
<ref id="B258-ijms-19-01212">
<label>258.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pontes</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Carneiro-Sampaio</surname>
<given-names>M.M.S.</given-names>
</name>
<name>
<surname>Markus</surname>
<given-names>R.P.</given-names>
</name>
</person-group>
<article-title>Pineal melatonin and the innate immune response: The TNF-alpha increase after cesarean section suppresses nocturnal melatonin production</article-title>
<source/>J. Pineal Res.
          <year>2007</year>
<volume>43</volume>
<fpage>365</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2007.00487.x</pub-id>
<pub-id pub-id-type="pmid">17910605</pub-id>
</element-citation>
</ref>
<ref id="B259-ijms-19-01212">
<label>259.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kallaur</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Simão</surname>
<given-names>A.N.C.</given-names>
</name>
<name>
<surname>Alfieri</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Flauzino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>de Carvalho Jennings Pereira</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>de Meleck Proença</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Borelli</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Kaimen-Maciel</surname>
<given-names>D.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability</article-title>
<source/>Mol. Neurobiol.
          <year>2017</year>
<volume>54</volume>
<fpage>2950</fpage>
<lpage>2960</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-016-9846-x</pub-id>
<pub-id pub-id-type="pmid">27023227</pub-id>
</element-citation>
</ref>
<ref id="B260-ijms-19-01212">
<label>260.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Álvarez-Sánchez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cruz-Chamorro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>López-González</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Utrilla</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Fernández-Santos</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Martínez-López</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lardone</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Guerrero</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Carrillo-Vico</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance</article-title>
<source/>Brain. Behav. Immun.
          <year>2015</year>
<volume>50</volume>
<fpage>101</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2015.06.021</pub-id>
<pub-id pub-id-type="pmid">26130320</pub-id>
</element-citation>
</ref>
<ref id="B261-ijms-19-01212">
<label>261.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Constantinescu</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Hilliard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ventura</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rostami</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis</article-title>
<source/>Pathobiology
          <year>1997</year>
<volume>65</volume>
<fpage>190</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1159/000164122</pub-id>
<pub-id pub-id-type="pmid">9396042</pub-id>
</element-citation>
</ref>
<ref id="B262-ijms-19-01212">
<label>262.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wie</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1</article-title>
<source/>J. Vet. Sci.
          <year>2001</year>
<volume>2</volume>
<fpage>85</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">14614276</pub-id>
</element-citation>
</ref>
<ref id="B263-ijms-19-01212">
<label>263.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giese</surname>
<given-names>K.P.</given-names>
</name>
</person-group>
<article-title>GSK-3: A key player in neurodegeneration and memory</article-title>
<source/>IUBMB Life
          <year>2009</year>
<volume>61</volume>
<fpage>516</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1002/iub.187</pub-id>
<pub-id pub-id-type="pmid">19391164</pub-id>
</element-citation>
</ref>
<ref id="B264-ijms-19-01212">
<label>264.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoppe</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Frozza</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Comiran</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Battastini</surname>
<given-names>A.M.O.</given-names>
</name>
<name>
<surname>Salbego</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: Involvement of GSK-3beta, tau and neuroinflammation</article-title>
<source/>J. Pineal Res.
          <year>2010</year>
<volume>48</volume>
<fpage>230</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2010.00747.x</pub-id>
<pub-id pub-id-type="pmid">20136701</pub-id>
</element-citation>
</ref>
<ref id="B265-ijms-19-01212">
<label>265.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guven</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Taskin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Akcakaya</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Melatonin Prevents Mitochondrial Damage Induced by Doxorubicin in Mouse Fibroblasts Through Ampk-Ppar Gamma-Dependent Mechanisms</article-title>
<source/>Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.
          <year>2016</year>
<volume>22</volume>
<fpage>438</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="doi">10.12659/MSM.897114</pub-id>
</element-citation>
</ref>
<ref id="B266-ijms-19-01212">
<label>266.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ogasawara</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kizaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Izawa</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Melatonin promotes adipogenesis and mitochondrial biogenesis in 3T3-L1 preadipocytes</article-title>
<source/>J. Pineal Res.
          <year>2015</year>
<volume>59</volume>
<fpage>267</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12259</pub-id>
<pub-id pub-id-type="pmid">26123001</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-19-01212-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>The canonical WNT/β-catenin pathway. (<bold>A</bold>) Under physiological circumstances, the WNT “off state”, the cytosolic β-catenin is bound to its destruction complex, consisting of adenomatous polyposis coli (APC), AXIN and glycogen synthase kinase-3β (GSK-3β). After CK-1 phosphorylates on Ser45 residue, β-catenin is further phosphorylated on Thr41, Ser37, and Ser33 residues by GSK-3β. Then, phosphorylated β-catenin is degraded into the proteasome. Therefore, the cytosolic level of β-catenin is kept low in the absence of WNT ligands. If β-catenin is not present in the nucleus, the T-cell factor/lymphoid enhancer factor (TCF/LEF) complex cannot activate the target genes. Dickkopf (DKK) can inhibit the WNT/β-catenin pathway by binding to WNT ligands or low-density lipoprotein receptor-related protein 5/6 (LRP 5/6). (<bold>B</bold>) When WNT ligands bind to both Frizzled (FZD) and LRP 5/6, the WNT “on state”, Disheveled (DSH) is recruited and phosphorylated by FZD. Phosphorylated DSH in turn recruits AXIN, which dissociates the β-catenin destruction complex. Therefore, β-catenin escapes from phosphorylation and subsequently accumulates in the cytosol. The accumulated cytosolic β-catenin goes into the nucleus, where it binds to TCF/LEF and activates the transcription of target genes.</p>
</caption>
<graphic xlink:href="ijms-19-01212-g001"></graphic>
</fig>
<fig id="ijms-19-01212-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Aerobic glycolysis stimulation by activated canonical WNT/β-catenin pathway. Activation of the receptor tyrosine kinase (RTK) is required to take up enough glucose to cell survival. PI3K/Akt pathway is stimulated to maintain a sufficient ATP production through the metabolism of glucose. Glucose is transformed into pyruvate into the mitochondria for the oxidative phosphorylation process. However, during WNT activation, WNT signal transduction results in activation of c-Myc, lactate dehydrogenase A (LDH-A), pyruvate dehydrogenase kinase (PDK) and monocarboxylate transporter 1 (MCT-1). The WNT target genes cooperate to divert glycolytically derived pyruvate into lactate which is expelled out the cell by MCT-1. Moreover, c-Myc induces glutamine uptake and glutaminolysis to support mitochondrial integrity and aspartate production. Accumulation of cytosolic lactate involves several pathways such as nucleotide synthesis, lipid synthesis and cell division.</p>
</caption>
<graphic xlink:href="ijms-19-01212-g002"></graphic>
</fig>
<fig id="ijms-19-01212-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Circadian clock genes process. The clock is considered as a stimulatory loop, with the Bmal1/Clock heterodimer activating the transcription of Period (Per) and Cryptochrome (Cry) genes, and then a negative feedback loop with the Per/Cry heterodimer which translocates to the nucleus and then represses the transcription of the Clock and Bmal1 genes. An additional loop implicates the RORs and Rev Erbs factors with a positive feedback by retinoid-related orphan receptors (ROR) and a negative feedback by Rev Erbs. Arrows: activation; T bar: inhibition.</p>
</caption>
<graphic xlink:href="ijms-19-01212-g003"></graphic>
</fig>
<fig id="ijms-19-01212-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Schematic interaction between WNT, peroxisome proliferator-activated receptor γ (PPARγ) and circadian rhythms. PPARγ agonists can decrease Bmal1 expression. The knockout of Bmal1 leads to decrease WNT/β-catenin pathway activity and then in absence of initiation of aerobic glycolysis. In parallel, PPARγ agonists can decrease melatonin levels leading to activate GSK-3β activity, the main inhibitor of WNT pathway.</p>
</caption>
<graphic xlink:href="ijms-19-01212-g004"></graphic>
</fig>
<fig id="ijms-19-01212-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Potential PPARγ agonists treatment approach in demyelination. During acute phase, inflammation processes, activated by disruption of circadian rhythms, lead to release of several cytokines and pro-inflammatory factors which stimulate the canonical WNT/β-catenin pathway. Activation of the WNT ligands involves WNT target genes that are responsible for the initiation of the shunt of the tricarboxylic acid (TCA) resulting in aerobic glycolysis instead of oxidative phosphorylation. Lactate production, the main factor of energy metabolism alteration, and its release out the cells enhance CD4<sup>+</sup> T cells dysfunction which aggravates MS pathogenesis, neuronal and axonal damages. Using PPARγ agonists could be interesting because of their four interactions in the demyelination cascade. First, PPARγ agonists directly inhibits neuroinflammation by inhibiting cytokines and inflammatory factors release. Secondly, PPARγ agonists can regulate circadian clocks, such as Bmal1, to decrease inflammatory factors release and to target WNT ligands. Third, their opposed interaction with the canonical WNT/β-catenin pathway can prevent the initiation of aerobic glycolysis process and then the energy metabolism reprogramming enable MS. At last, PPARγ agonists have neuroprotective effects by targeting CD4<sup>+</sup> T cells to prevent neuronal and axonal damages. Arrow: activation; T bar: inhibition.</p>
</caption>
<graphic xlink:href="ijms-19-01212-g005"></graphic>
</fig>
<table-wrap id="ijms-19-01212-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-19-01212-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>WNT pathway, peroxisome proliferator-activated receptor γ (PPARγ) and aerobic glycolysis in multiple sclerosis (MS) models.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Expression</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Actions</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<bold>PPARγ</bold>
</td>
<td align="center" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">Agonists</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Inhibition of NF-κB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B114-ijms-19-01212">114</xref>,<xref ref-type="bibr" rid="B115-ijms-19-01212">115</xref>,<xref ref-type="bibr" rid="B116-ijms-19-01212">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Decrease inflammation, permits remyelination</td>
<td align="center" colspan="1" rowspan="1" valign="middle">OLs models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B118-ijms-19-01212">118</xref>,<xref ref-type="bibr" rid="B119-ijms-19-01212">119</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuroprotection</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B121-ijms-19-01212">121</xref>,<xref ref-type="bibr" rid="B122-ijms-19-01212">122</xref>,<xref ref-type="bibr" rid="B123-ijms-19-01212">123</xref>,<xref ref-type="bibr" rid="B124-ijms-19-01212">124</xref>,<xref ref-type="bibr" rid="B125-ijms-19-01212">125</xref>,<xref ref-type="bibr" rid="B126-ijms-19-01212">126</xref>,<xref ref-type="bibr" rid="B127-ijms-19-01212">127</xref>,<xref ref-type="bibr" rid="B128-ijms-19-01212">128</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Th17 differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Murine CD4<sup>+</sup> T cells</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B129-ijms-19-01212">129</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Decrease IL-17 expression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B130-ijms-19-01212">130</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Decrease IL-1, IL-6 and COX2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B142-ijms-19-01212">142</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decrease β-catenin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B142-ijms-19-01212">142</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
<bold>WNT</bold>
</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Overexpression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Chronic pain</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B68-ijms-19-01212">68</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Impairs OPC differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B137-ijms-19-01212">137</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Alteration of endothelial adherens</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B139-ijms-19-01212">139</xref>,<xref ref-type="bibr" rid="B140-ijms-19-01212">140</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Alteration of endothelial adherens</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">MS brain tissue</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B141-ijms-19-01212">141</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
<bold>Aerobic Glycolysis</bold>
</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Activation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuronal cell death and astrocytic inflammation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">EAE models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B166-ijms-19-01212">166</xref>,<xref ref-type="bibr" rid="B167-ijms-19-01212">167</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MS progression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Human models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B172-ijms-19-01212">172</xref>,<xref ref-type="bibr" rid="B173-ijms-19-01212">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased lactate production</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Human models</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B31-ijms-19-01212">31</xref>,<xref ref-type="bibr" rid="B159-ijms-19-01212">159</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mitochondrial dysregulation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human models</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B175-ijms-19-01212">175</xref>,<xref ref-type="bibr" rid="B176-ijms-19-01212">176</xref>,<xref ref-type="bibr" rid="B177-ijms-19-01212">177</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>NF-κB: nuclear factor-κB; EAE: experimental autoimmune encephalomyelitis; OLs: oligodendrocytes; OPC: oligodendrocyte precursor cells; MS: multiple sclerosis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>